Dr Qihe Xu's Academic CV

Signature: Qihe Xu

TABLE OF CONTENTS	PAGE
中文概要 (Executive Summary in Chinese)	1-3
General information	4
Education and Qualifications	4
Professional History	4
Other Appointments and Affiliations	4-5
Leadership and Charitable Work	5
Awards, Honours & Named Main Collaborators	6
Grants, Fundraising & Research Incomes	7-8
Peer-Reviewed FP7 GP-TCM Reports, Guidelines, Theoretical article, Literature Studies, Editorials, Letters, Reviews, Data Science, Book Chapters, Translated Book	8-12
Peer-Reviewed Primary Research Papers	12-15
Dissemination & Outreach: Articles	16
Dissemination & Outreach: Other Activities	16-20
Invited Talks & Lectures	20-27
Invited Chair/Moderator/Panellist	27-29
Administration & Enabling Activities	29-33
Editorship and Editorial Board	33
Peer Expert Evaluation Activities	33
Professional Training	33-34
Expertise	34
Student and Staff Supervision	34
Mentorship	37
Tutorship & Pastoral Care	37
Teaching, Including Recruitment, Examining and Interviewing	38
Executive Summary Highlighting Research Discoveries	44-45
Executive Summary Highlighting Teaching Innovation	46-47

Dr Qihe Xu (徐启河博士)：微信号: qxu1999; 电邮: qihe.xu@kcl.ac.uk

Executive Summary in Chinese (中文概要)

工作经历

2006.7 至今 ： 伦敦国王学院终身讲席，历任讲师、高级讲师、整合中医药中心共同主任、主任

2005.6-2006.6： 美国国立卫生研究院肾脏病科礼遇副研究员

1999.2-2006.7： 伦敦大学学院肾脏病中心博士后、资深研究员、荣誉讲师

1992.9-1999.2： 中国人民解放军总医院肾内科住院医师、主治医师、讲师

教育背景

1998： 中国人民解放军总医院、军医进修学院内科学（肾脏病学）博士学位，导师陈香美院士

1992： 北京医科大学第一医院肾内科临床技能训练与研究硕士学位，导师刘平、李惊子教授

1989： 新乡医学院临床医学医疗系本科毕业

专长概述： 10 年临床背景，20 年欧美历炼，30 年整合医学、肾脏病学、药理学、分子生物学研究，主攻维甲酸生物学与药理学、纤维化与抗纤维化疗法、生物医药与中医药研究国际合作与规范。

简历概述：徐启河，英籍华人，1967 年 11 月生于河南省获嘉县。现任伦敦国王学院肾脏科学与整合中医药研究室首席科学家、高级讲师、中医药规范研究学会理事兼药理毒理兴趣组共同主席、国际中医药学会理事、中药全球化联盟英国地区协调人、世界中医药联合会道地药材多维评价专业委员会副会长和临床安全用药等专业委员会常务理事、世界中医药杂志英文刊（WJTCM）副主编，*Sci Rep*、*Exp Biol Med*、***J Integr Med*** 等编委、北京中医药大学和成都中医药大学客座教授。曾在国内从事中西医结合肾脏病学临床与基础研究 10 年。1997 年，受中华肾脏病学会和国际肾脏病学会（ISN）联合举荐接受 ISN 资助，赴澳大利亚参加 ISN 年会，并到皇家墨尔本医院见习。1998 年，任解放军总医院肾科主治医师，带领病房连续三季度获得大内科临床部总评前两名，获永久性“白求恩杯”，荣立三等功。1999-2001 年，受 ISN 奖学金资助，赴伦敦大学大学学院深造，在大内科主任、临床医学院院长、国际著名肾脏病学家 Leon Fine 教授指导下开展博士后研究，并留校任荣誉讲师。2005 年受美国国立卫生研究院（NIH）资助，赴 NIH 医学中心肾科开展合作研究一年，并与现任科主任 Jeffrey Kopp 教授建立了密切合作。2006 年，应 Bruce Hendry 教授（前英国肾脏病学会主席）之邀加盟伦敦大学国王学院，担任终身教席讲师、博士和博士后导师，2010 年晋升高级讲师。作为课题负责人获中国国家自然科学基金、欧盟委员会、英国皇家学会、英国肾脏研究基金会、英国心脏基金会和中英科技创新计划等资助逾 200 万英镑。2009-2012 年，作为首席科学家成功组织、领导与实施了欧盟第七框架计划百万欧元欧-中合作《后基因组时代传统中医药研究的良好实践》重大专项，并领导成立了中医药规范研究学会，为中医药规范的制定和推广，以及中医药科研国际合作提供了可持续发展的平台。2013 年以来，负责筹建伦敦国王学院整合中医药中心，并担任医学生导师、药理系本科招生官、硕士生科研项目召集人。2020 年，因在国王学院开拓整合中医药高等教育与科学研究，以及在 GP-TCM 与中医药规范研究学会等中医药研究国际合作中发挥的领导作用，荣获中华中医药学会科学技术奖 · 岐黄国际奖。2015-2022 年，全球仅有 14 位科学家获此殊荣。在 *Lancet*, *Science*、*J Biol Chem* 、*Kidney Int* 、 *Br J Pharmacol* 、 *J Ethnopharmacol* 、*Phytomedicine* 等发表文章逾百篇，主编 *J Ethnopharmacol* 特刊 1 期、参编 Frontiers 专题 3 集，副主编论著 1 部、总校对 1 部，参编 6 部，H-index 33，合计影响因子逾 600。121 篇论文单篇被引逾 100 次，4 篇被引用超 200 次。

教育创新：2012 年, 竞选成功出任伦敦大学国王学院学术委员会委员，代表医学院资深教员参与大学教学、科研和后勤的决策，以及与大学高层的对话，为学校的发展献计献策。作为导师，培养了博士生三名、博士后三名。担任多名博士生指导委员会的主席或委员，以及多名少数族裔博士后、讲师的事业发展顾问。担任药理系本科生招生官，负责本科招生的全过程；担任医学生药理学教学以及药理学间插学位课程负责人， 着力培养临床药理人才；担任药理系硕士班课题召集人，负责组织超过半数的教学单元，为该课程从数量、质量到学生满意率的全优成绩做出了核心贡献。每年担任

15-21 名医学生导师，指导学生从入学到毕业的全过程；总结出独特的、富有成效的 APP (成年-专业-主动)三原则，作为指南，深受学生们的欢迎。 为医学生和基础医学院学生开设了特色选修课《健卫工作者为何要关注中医药》、《中医药现代化》、《草药的重要性》、《草药与健康》等，教学成果在学术会议和期刊发表，取得了较好的社会影响。譬如，发表草药研究重要性以及如何提高研究质量的 eJTCM 评述被引 137 次；深入分析中草药防治急性肾损伤的潜在价值，文章在 WJTCM 发表后，成为本人学术网页上下载最多的文章（逾 700 次）；合作发表《科学》特刊文章，提出草药毒理学研究和预防的整合策略；组织医学生和临床专家研讨草药的肾毒性问题，并提出了创新的解决方案，《驯服肾毒性草药之火》在 WJTCM 发表后受到伦敦国王学院、英国肾脏病基金会、英国肾脏学会会刊专题推介, 同名讲座在世界中医药学会联合会临床安全用药专业委员会 2021 年会上引起强烈反响。2022 年 6 月，在英国肾脏病学年会上组织再教育专题讲座《关于草药及其与药物的相互作用，肾病患者和健卫工作者应知道些什么》；8 月带领医学生完成范围系统综述《草药在睾丸和男性生育健康与疾病中的作用》，发表于 *Phytomedicine* 中医药规范研究学会 10 周年*纪念*专集。

科研创新：在中、英、美顶尖肾脏病中心研究中西医结合肾脏病防治 30 余年。1989-99 年在国内从事内科肾脏病学临床与科研，发表论文 30 余篇，其中 10 篇单篇被引 30-221 次。1989-92 年，硕士研究生课题聚焦慢性肾衰患者钙磷代谢紊乱、肾性骨病无创性诊断与牡蛎粉治疗的临床研究。1992-98 年，博士生课题研究肾小球内凝血导致肾损伤的细胞分子生物学原理和水蛭、水蛭素、小分子肝素治疗的系列临床与基础研究，论著发表于 *Kidney Int* (1999)。1995 年作为项目负责人获得国家自然科学基金青年项目资助，2001 年获国家科技进步二等奖（第三受奖人），2002 年入选国家自然科学基金"慢性进展性肾病的发病机理与防治"创新研究群体。

2001-03 年在伦敦大学学院肾脏病中心的博士后研究聚焦药用维甲酸防御过氧化损伤以及防治肾脏病的机理，在欧洲肾脏病学会、英国药理学会、美国生物化学学会会刊发表系列文章，其中 7 篇单篇被引超过 60 次。近十余年，作为课题组负责人，聚焦内源性维甲酸，明确了其在肾脏的生理活性局限于集合管，并明确揭示了维甲酸在集合管细胞内调控的一系列具有防御功能的基因。受《黄帝内经》正气存内邪不可干理论启发，首创《集合管肾脏中心防御》假说，认为肾脏集合管及其维甲酸信号是肾脏防御的重要机制，而现代科学对肾脏防御机制认识的不足是西医防治肾损伤不怎么成功的重要原因。2019 年，应邀在英国肾脏病学年会上作专题报告，并受 Nephron 主编邀请，以"特别文章"形式发表了这一原创学术思想。2020 年，发现集合管细胞内维甲酸信号能感知肾损伤因子，并对急、慢性损伤因子做出相反反应，支持其可能在肾脏的防御中发挥重要作用。

在英国肾脏研究基金会、"中英科技创新计划"资助下，采用本实验室首创的、可定量的、适合于高通量筛选的模型(被引 176 次)开展抗纤维化、促纤维化中草药研究，发现多个扶正、活血化瘀、化痰、清热解毒单味中药、复方和草药化合物具有抗纤维化活性，而益母草等具有促纤维化活性。该系列研究发表于欧洲肾脏病学会会刊（2009）等，单篇被引 139 次；发表于《科学》特刊（2014）的成果综述被国际传媒广泛报道；该特刊还入选了世界中医药学会联合会发布的"2014 年世界中医药十大新闻"。在此基础上，积极推动组学技术在中医药研究的应用，两篇发表于 2012 年的代表性论文分别被引 85、246 次；指导博士研究生采用蛋白组学方法，阐明成纤维细胞活化的系统生物学原理（*Sci Rep* 2020），揭示了黄芩、黄芩素等抗纤维化药物的网络药理学原理（*Phytomedicine* 2022）。

2012 年以来，在伦敦国王学院这一欧洲最大的健康专业人才培养中心牵头筹建"国王学院整合中医药学中心"（https://chinese.kingscicm.org），2013 获准，2016 年开始与大学资金募集团队合作; 2025 年疫情后重启一周年再次成为大学资金募集与伙伴建设重点——据 2026 年 QS 全球大学专业排名，伦敦国王学院各健康相关专业均位居世界前 20。其中，护理第 2、牙科第 5、生命科学与医学第 9。

研究方向：在中医正气、阳气、补泻结合、阴阳调理的理论指导下，研究肾脏急、慢性损伤易感性机理和代谢学原理，通过尿液细胞 snRNA-seq、亚细胞与无细胞成分"液体活检"提供肾脏防御机能、健康状况无创诊断，采用"补法"、代谢干预等预防、治疗肾脏病等炎症、纤维化性疾病。重点研

究集合管和肾小球壁层上皮细胞维甲酸信号在防御急、慢性肾损伤机制中的作用、中药对肾脏防御机制的调节，组学、系统生物学和网络药理学指导下开展纤维化机理研究，通过调节信号转导与代谢干预，双管齐下，多靶点阻断纤维化。

合作交流：旅英 26 年，践行"以沟通促合作"的理念，促进中西交流和相互学习，积极为祖国、为整合中医药服务。千禧年初，担任伦敦中心中国学生学者联谊会执委和主席、全英中国学生学者联谊会秘书长，负责组织接待数十家国内各省市的访问、交流、人才招聘活动，在伦敦大学学生会组织了由主要业界领袖和利益攸关方参加的里程碑式的研讨会《中医在英国：机遇与挑战》(2000)，还邀请资深中医师在全英华人生命科学学会年会上作报告，为中医药研究牵线搭桥。担任全英华人生命科学学会主席(2007-2009)期间积极组织"春晖计划"等为国服务项目，领导成立了由具有高级职称的各大学和各大生物医药企业华人学者，成立全英华人生命科学院，担任创院副院长，为在更高层面上为祖国服务提供了新的平台[1]。

在英国开拓整合中医药事业缺乏文化和资金的支持，无异于在沙漠上建绿洲[2,3]。2007 年，作为首席科学家组织并领导跨学科的英-中合作团队，成功竞标英国肾脏研究基金会面上项目，开展抗纤维化、促纤维化中草药研究——这是该基金至今唯一的草药研究项目。2009 年，作为首席科学家组建、带领团队竞标欧盟框架计划有史以来唯一的中医药领域重大欧-中合作协调专项，并从 13 个竞标的团队中脱颖而出，获得欧盟百万欧元资助。2009-12 年，在欧洲金融危机的严峻背景下，带领《后基因组时代传统中医药研究的良好实践》（GP-TCM）协作组成长为涵盖 24 个国家、逾百单位(含 31 个中国大学院所和企业)、200 多名科学家的大协作。协作组致力于拓展和推广中医药研究各领域的规范，起草、编辑、审核了向欧盟委员会提交的 117 份研究报告，为欧-中中医药科研合作提供了科学依据和指南[4]。2012 年，受邀共同主编 *J Ethnopharmacol* GP-TCM 专集，该专集中的 20 篇论文单篇平均被引近 200 次。领衔的总论定义了中医药现代化及其亟需的规范，总结了协作组 10 个工作组的主要成就，指明了欧-中中医药科研合作的机遇、挑战和优先发展领域。重点参与编著的两篇关于组学技术在中医药领域应用和中医药论文撰写规范的文章单篇分别被引逾 200 次。

为了促进欧-中中医药现代化合作的可持续发展，作为筹备委员会主席于 2012 年领导创立中医药规范研究学会，先后担任创会副会长、常务理事、理事等，为学会成长为信誉良好的慈善组织、权威的欧盟药监局顾问机构、宝贵的中医药国际化合作交流平台做出了核心贡献[5]。2013 年，牵头在 *BMC Complement Altern Med* 发表学会白皮书，提出了中医药现代化的"三段论"，阐释了内涵丰富的三"I"指导原则：integrity（守正、求是、规范）、integration（多维整合）、innovation（优化创新），被引近 300 次[6]。2008-2020 年，为了凝聚队伍、促进交流，十三年如一日，主编、共同主编《GP-TCM 信息通报》（2012 年更名为《中医药规范研究学会信息通报》）逾百期。该英文通报追求即时、专业、权威、公正，被誉为中医药规范研究学会最好的名片之一、中医药国际传播的一面旗帜。2020 年以来，积极致力于抗疫合作与交流，作为科学家代表，参与了英国肾脏病学会疫情期间肾脏替代疗法最佳规范和系统抗压能力建设的制订；同时，积极为中医药参与英国抗疫牵线搭桥，通过微信公众号、现代化中医药国际协会成立二十周年纪念特刊等，介绍中医药助力英国抗疫取得的成就，以及面临的机遇与挑战[7]。与祖国的合作是 GP-TCM 项目的重中之重。在新冠疫情爆发前的 10 年余里，应邀在祖国的 11 个省、20 多个城市发表了 53 场演讲，并与祖国大陆以及港澳台的高校院所、企业建立了合作。在亚洲、欧洲、美洲的 10 个国家的全国或国际大会上发表演讲，促进中医药国际交流。疫情过后，积极在国际、国内传播中医药、整合医药研发的国际标准与规范，推动以"守正、求是、规范"为基础，以"多纬整合"为主要路径的医药优化创新与国际合作。

[1] http://www.clss.org.uk/ALSC-UK/ALSC-UK.html
[2] https://www.shkjb.com/content.html?id=152271
[3] http://www.gp-tcm.org/wp-content/uploads/2022/04/Jun-2019-GP-TCM-RA-NL.pdf
[4] https://cordis.europa.eu/project/id/223154/reporting/
[5] http://www.gp-tcm.org
[6] https://bmccomplementmedtherapies.biomedcentral.com/articles/10.1186/1472-6882-13-132
[7] https://mp.weixin.qq.com/s/VLA02U3yB7FXDB-BqrlT5Q

GENERAL INFORMATION

Nationality: British **DoB:** November 1967 **Gender:** Male

Contact details: Dr Qihe Xu, Renal Sciences and Integrative Chinese Medicine Laboratory, King's College London, Weston Education Centre, 10 Cutcombe Road, London SE5 9RJ, UK. Tel: +44 207 848 5108; e-mail: qihe.xu@kcl.ac.uk

EDUCATION AND QUALIFICATIONS

1995-1998 Doctor's Degree of Medicine in Molecular Nephrology (equivalent to **PhD)**, PLA Postgraduate School of Medicine, Beijing, China.

1989-1992 Master's Degree of Medicine in Clinical Nephrology (equivalent to **MD)**, Peking University 1st Hospital, Peking University, Beijing, China.

1984-1989 Bachelor's Degree in Clinical Medicine (equivalent to **MBBS**), Dept. of Medicine, Xinxiang Medical University, Henan, China.

PROFESSIONAL HISTORY

2025 Associate Member, Lau China Institute, KCL.

2014- Faculty member, Department of Pharmacology & Therapeutics, King's College London (KCL), London, UK.

2013- Co-Director/Director, King's Centre of Integrative Chinese Medicine, KCL.

2010- Senior Lecturer in Renal Medicine, KCL, London, UK.

2006-2009 Lecturer in Renal Medicine, KCL, London, UK.

2005-2006 Courtesy Associate, NIDDK, NIH, USA (10 months).

2001-2006 Honorary Lecturer and Senior Fellow, Centre for Nephrology, Division of Medicine, Royal Free & University College Medical School, University College London (UCL), London, UK.

1999-2001 Postdoctoral Research Fellow, Centre for Nephrology, Division of Medicine, Royal Free & University College Medical School, UCL, London, UK.

1995-1999 Attending Physician and Lecturer, Department of Nephrology, the General Hospital of the Chinese PLA, Beijing, China.

1992-1995 Resident Physician and Instructor, Department of Nephrology, the General Hospital of the Chinese PLA, Beijing, China.

1989-1992 Resident Physician, Department of Nephrology, Beijing Peking University 1st Hospital, Beijing, China.

OTHER APPOINTMENTS AND AFFILIATIONS

2025–2030 Council Member, Speciality Committee of Chinese Materia Medica, World Federation of Chinese Medicine Societies (WFCMS)

2022–2026 Vice-Chair, Li Shizhen Medical Research and Its Utility Speciality Committee, WFCMS

Standing Committee Member, TCM Innovative Drug Development Speciality Committee, WFCMS

2021-2024 Guest Professor, Beijing University of Chinese Medicine.

2020- Board Member, International Society of Chinese Medicine

2019-2022 Guest Professor, Chengdu University of Traditional Chinese Medicine Affiliated Hospital and Sichuan Provincial TCM Hospital, Chengdu, China.

2017-2022 Standing Committee Member, Clinical Drug Safety Speciality Committee, WFCMS

2015-2022 Vice-Chair, the Geoauthentic Herb Multi-dimensional Evaluation Specialty Committee, WFCMS

2012- Founder Life Member, elected Member of the Board of Directors (2012-2014; 2017-2026), Founder Vice President (2012-2014) and Newsletter Co-Editor (2008-2016), Editor-in-chief (2017-2020) and Consulting Editor (2020-2021), of the GP-TCM Research Association.

2012 Visiting Professor, College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

2010-2011 Member, The American Physiological Society.

2007- Member, Renal Association, the United Kingdom.

2006- Honorary Professor, Xinxiang Medical College, Henan, China.

2006- Honorary Professor, Zhengzhou University, Henan, China.

2006-2016 Member, American Society of Nephrology.

2006 Committee member, National Society of Medical Scientists – Chinese American Association: http://www.nsms-caa.org/nsms-caa/structure.html

2001- Fellow, International Society of Nephrology.

LEADERSHIP AND CHARITABLE WORK

- Serving as the UK Regional Coordinator, Consortium for Globalisation of Chinese Medicine (since 2024). The Consortium aims at promoting modernisation of traditional Chinese medicine (TCM) so that it can better serve the needs of all peoples on the globe by bringing together industrial and regulatory agencies under an academic collaboration arrangement focusing on several areas and Working Groups: Quality control of herbal product; herbal and nature product resources & cultivation; mechanism and toxicity study of polychemical medicine.
- Led the founding of the GP-TCM RA, elected Member of the Board of Directors (2012-2014; 2017-2024) and served as Founder Vice President (2012-2014) and Newsletter Co-Editor (2008-2016), Editor-in-chief (2017-2020) and Consulting Editor (2020-2021): Founded in Leiden in 2012 by *Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era*, aka the GP-TCM project, a ground-breaking EU-China collaboration funded by European Union's Seventh Programme Framework, the GP-TCM RA has now established itself as an UK-based charity, an EMA/HMPC Interested Party and a renowned international society dedicated to promoting EU-China collaboration and good practices in TCM research using modern technologies. Currently, our Association has 15 members of Board of Directors, Chairs and Co-Chairs of 7 interest groups, 13 Corporate/Institutional members, and over 330 individual members from different parts of the world.
- Elected Academic Board Member (2012-2016), King's College London.
- Led founding King's CICM, King's Health Partners, serving as Co-Director (since 2013) and Director (since 2020).
- Coordinated and successfully delivered the €1.0m FP7 GP-TCM project (2009-2012).
- Chaired the Chinese *Life Scientists Society in the UK* (CLSS-UK, 2007-2009) and led founding of the *Academy of Life Sciences for Chinese in the UK* (ALSC-UK) in 2008: https://www.clss.org.uk/about-alsc-uk
- Presided over the Secretariat of *Chinese Students & Scholars Association* in the UK (CSSA-UK) and expanded its branches across the UK from ~30 in 2003 to ~70 in 2004.
- Chaired the *Chinese Students & Scholars Association* at University College London (CSSA-UCL) and led its registration at the University of London Union, 2002-2003.
- Having promoted physical exercise at King's and beyond since 2015: Led the development of the King's Table Tennis Club (Denmark Hill Campus), which has over 30 members; one of the core

founders and Board Members and Past Standing Vice-President of the *UK-Chinese (Ying-Hua) Table Tennis Club*, a not-for-profit organisation with over 400 members across the UK.

- Advisor of *The Chinese Legion UK*, an UK association for Chinese ex-servicemen.
- Served as Honorary Chairman (2021-2023), Vice Chairman (2018-2019) and Advisor (2019-2021) of *Xu's Clansmen Association UK.*

AWARDS, HONOURS & NAMED MAIN COLLABORATORS

2022	The second prize, *Chinese Medicine and Culture*, 2021: https://mp.weixin.qq.com/s/xkwcvbyTVyp8OB75GeSe3g
2022	Supervised Dr Hailin Zhu to secure a two-year China Scholarship Council Postdoctoral Fellowship.
2020	Qihuang International Prize, China Association of Chinese Medicine (Prize reference No. QH2020-01): US$ 10,000 — one of the two awardees of the year; since its inception and until 2021, only 13 scientists worldwide have been honoured by this prestigious prize.
2014-2015	International expert short-term visit award by the Taiwan Ministry of Science & Technology. NT$ 82,250 (51000 for air tickets + 6,250 x 5 days for living costs).
2014-2018	Supported Miss Shujun Zhou to secure a Sino-British Fellowship Trust fellowship award to partially support her Chinese medicine-focused PhD training at King's College London, £18,000.
2013-2016	Beijing University of Chinese Medicine Invites EU's GP-TCM Experts to Exchange in Education and Research. Ministry of Education, China, 600,000 RMB Yuan. PI: Dr. Ling Dong and Prof. Yanjiang Qiao, Beijing University of Chinese Medicine, China.
2013-2015	Using Chinese herbs to slow down renal failure. Hong Kong Innovation & Technology Fund. HK$1,449,998. PI: Prof. PC Leung, Chinese University of Hong Kong, Hong Kong SAR, China.
2013	Supported Dr. Fan Qu, Associate Professor, School of Medicine, Zhejiang University to secure a China Scholarship Council Fellowship Award, including travel and living expenses and 1000 pounds of bench fees, which will aim to work at King's College London for 1 year, to start from the 2nd half of 2014.
2012	Supported Naima Saeed, a PhD student of Quaid I Azam University Islamabad, Pakistan, to secure a scholarship, including travel and living expenses and £1750 of bench fees, which allowed her to work at King's College London for 6 months between December 2012 and May 2013.
2012	The 10th Anniversary Outstanding Contribution Award, Federation of UK Guangdong Chinese
2011-2013	ChinaMed: Traditional Chinese medicine machine translation and information service. Ministry of Science & Technology International Cooperation Programme. 2,000,000 RMB Yuan. PI: Yanhuai Liu, President of BeiJing East Linden Science & Technology Co., Ltd, Beijing, China: en.chinamedis.com; http://www.eastlinden.net
2010	A prize of £100 awarded to my PhD student, Yuen Fei Wong, for being selected to represent the Division of Gene and Cell Based Therapy to present her work in the 2010 King's Graduate Research.
2010	King's Continuation Scholarship (KCS) was awarded to my PhD student Yuen Fei Wong for her excellence in research.
2008	China Science Network Award jointly by the Royal Society (UK) and the China Scholarship Council (CSC) to support face-to-face meetings with Dr Jian Li, Prof Jianzhao Niu and Prof Jifeng Wang (Beijing University of Chinese Medicine) in

Beijing to discuss collaborations on anti-fibrotic herbal medicine research. £700 towards international airfare and living expenses in Beijing.

2007 Abbott Renal Care Advisory Board: Selective Vitamin D Receptor Activators as a New Therapeutic Approach to Secondary Hyperparathyroidism

2005-2006 Wellcome Trust Value in People Award.

2005-2006 National Institutes of Health Courtesy Associate Fellowship (USA).

2005-2006 UCL Bogue Fellowship.

2003 Outstanding Pastoral Care Service Award, the Education Section of the Chinese Embassy in the UK.

2001 The 2nd class national award for scientific and technological advances, the Central Government of the P. R. China (The 3rd author, Award No. 123.J-233-2-06).

1998-2001 International Society of Nephrology Fellowship.

1998 Annual best paper award, the General Hospital of the Chinese PLA.

1998 The class 3 medal for achievements in clinical practice, research and teaching, the General Hospital of the Chinese PLA.

1997 International Society of Nephrology Scholarship, US $5, 000.

GRANTS, FUNDRAISING & RESEARCH INCOMES

2025 **Xu Q.** Award Title: "UKKW2025 Session: "Glomerular Parietal Epithelial Cells: An Exciting Frontier in Renal Cell Biology." Grant Award: Sponsor_24/25_2. £2,000.

2025 **XU Q.** A philanthropist donation by Dr L-T Zhao in support of the 1st Honorary Advisory Board Meeting and the Inaugural Forum of the King's CICM initiative 2.0, £1,000.

2025 **XU Q.** A philanthropist donation by Phoenix Medical Group in support of the development of a fundraising website for the King's CICM initiative 2.0, £3,000.

2024-2026 **Xu Q** (PI)**,** Kopp JB. *ALDH1A2* Variants in Patients with Nephrotic Syndrome. Data-only ancillary study, The Nephrotic Syndrome Study Network (NEPTUNE), a North American multi-centre collaborative consortium aimed at better understanding the pathogenesis of, and investigating targeted therapies for, glomerular diseases, e.g., minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS) and membranous nephropathy (MN), which often manifest as nephrotic syndrome.

2022-2025 **Xu Q** (PI)**,** Wilson PD. Is normalising retinoic acid signalling a viable strategy for ARPKD? £10,000, The Polycystic Kidney Disease Charity, UK.

2019 **Xu Q.** Sponsorship towards a UK Kidney Week 2019 special session 'Mechanisms of Tubulointerstitial injury', 05 June 2019, £1500, Kidney Research UK.

2017-2020 Lin G, Ye Y, Fu PP, **Xu Q** (Co-I). Pyrrolizidine alkaloid-induced liver fibrosis: modelling and therapeutic intervention. HK$ 1,056,150, the General Research Fund, Hong Kong.

2017 **Xu Q** (PI). Partnership Fund (renewed), £3,000. King's College London

2016 **Xu Q** (PI). Partnership Fund, £3,000. King's College London

2015-2021 **Xu Q** (PI), Fraser D, Romagnani P, Hendry BM. MiR-acles in collecting ducts underlie albuminuria-induced renal fibrosis. Kidney Research UK Project Grant. £200,000.

2015-2016 Zhao ZZ, **Xu Q** (Co-I). Discovery of potential components attributed to pro-fibrotic activity of *Aconitum carmichaeli* Debx., Hong Kong Baptist University Faculty Research Grant Category II, HK$127,500.

2014-2017 **Xu Q** (PI), Peter Hylands, Bruce Hendry. PuraPharm PhD Scholarship, £90,000.

2014-2015 **Xu Q** (PI). Building a UK-China Partnership on Traditional Chinese Medicine and Natural Medicine. Department for Business, Innovation & Skills and Foreign & Commonwealth Office's Global Partnership Fund. £4,000.

2014- **Xu Q** (PI). King's Centre for Integrative Chinese Medicine Enabling Fund, £3,000. King's College London

2013- Wilson PD, **Xu Q** (Co-PI). A pilot study on the potential of dietary supplementation to slow ADPKD progression: Vitamin A regulation of cystic expansion by targeting the focal adhesion complex. The Polycystic Kidney Disease Charity, UK. £2,000.

2013- **Xu Q** (PI). King's College London-University of Hong Kong partnership travel grant. £1,500.

2011- **Xu Q** (PI). Initial seeding fund in support of establishing a Centre for Integrative Medicine Research, School of Medicine, King's College London. £10,000.

2011-2011 **Xu Q** (PI). Disseminating EU/UK TCM Research to Stakeholders in Shanghai. Global Partnerships Fund, UK Department of Business, Innovation and Skills, Project No. GPF 11, £1,200.

2010-2012 **Xu Q**, Hendry BM, Unwin RJ, Wilson PD. Retinoic acid in collecting ducts: What are its target genes? Kidney Research UK. £40,000.

2010- **Xu Q**. KCL-HKU partnership travel grant. £1,200.

2009-2013 Rankin A (Training fellow), Hendry BM (Supervisor), **Xu Q** (Supervisor). Dissecting the dual actions of retinoids in TGF-β1-induced renal fibrosis. Kidney Research UK. £220,250.

2008-2012 **Xu Q** (PI)**,** Hendry BM, Hylands P, Simmonds M, et al. Coordination and Support Programme, GP-TCM: Good practice in traditional Chinese Medicine Research in the post-genomic era. European Commission. €995,100.

2008-2009 **Xu Q** (PI). Event grant for organising a Sino-EU GP-TCM Workshop in Beijing 12-13th Jan. 2009. Innovation China UK, £15,000.

2008-2009 **Xu Q** (PI), Xu Q (Qing Xu), Hendry BM, Liang XM, Development of anti-fibrotic drugs from Chinese herbs. Innovation China UK, £30,000.

2007-2009 **Xu Q** (PI), Hendry BM, Hylands P, Simmonds M. Discovery, molecular mechanisms and biological identities of genuine anti-fibrotic herbs. Kidney Research UK, £100,000.

2006-2007 Kopp JB, **Xu Q** (Co-I), Shrivastav S. High-throughput screens for diabetic nephropathy using cell culture: identifying agents that prevent mesangial cell nodule formation and stabilize podocyte phenotype. NIH-JDRF Drug Screening Initiative: FDA1000.

2005-2006 **Xu Q** (PI). The anti-fibrotic effect of retinoids in mesangial cells. Royal Free Peter Samuel Grant. £7,000.

2003-2005 **Xu Q** (PI), Norman JT, Ruan XZ, Hong Y, Fine LG. Intracellular low density lipoprotein accumulation induced by hypoxia and retinoic acid: potential targets for the amelioration of atherosclerosis. British Heart Foundation, £98,809.

2002-2005 **Xu Q** (PI), Chen X. The clinical indices of ageing and ageing-related diseases. In: The "973" National Key Program Project, China: Mechanisms of ageing, prevention and treatment of ageing-related diseases. RMB ¥270,000.

1995-1998 **Xu Q** (PI), Li N, Wang J, Ye Y. Mechanisms of fibrin-related antigen-induced kidney injury, National Nature Science Foundation of China, RMB ¥90,000.

1995-1996 **Xu Q** (PI). Changes in renal cytokine expressing profile during acute tubular necrosis. The General Hospital of PLA Fund, RMB ¥20,000.

PEER-REVIEWED ARTICLES, BOOKS AND JOURNAL SPECIAL ISSUES

§ included in REF2021 submission.

* H-index 33: 13 papers and monographs with citations >100, five >200;

** Book or journal special issue; *** Book chapters;

**** National and international guidelines.

Peer-reviewed FP7 GP-TCM reports, guidelines, theoretical articles, literature studies, editorials, letters, reviews, data science & book chapters and translated book (n=54)

35 published in English

1. **Xu Q**. Therapies for systemic lupus erythematosus. Lancet 2024;404: 2162.
2. Liu W-B, Fermin D, Xu A-L, Kopp JB and **Xu Q**. Single-cell RNA sequencing data locate ALDH1A2-mediated retinoic acid synthetic pathway to glomerular parietal epithelial cells. Exp. Biol. Med. 2024; 249:10167.
3. Pu F, Li T, Shen C, Wang Y, Tang C, Zhang X, Yan L, **Xu Q**, Liu J. Fermented Ophiocordyceps sinensis mycelium products for preventing contrast-associated acute kidney injury: a systematic review of randomized controlled trials. Ren Fail. 2024;46:2300302.
4. **Xu Q**. WHO International Standard Terminologies on Traditional Chinese Medicine: Use in Context, Creatively. Integr Med Nephrol Androl. 2023;10:e00029.
5. Li J, Takasato M, **Xu Q**, Bijkerk R. Editorial: Epithelial plasticity and complexity in development, disease and regeneration. Front Cell Dev Biol. 2023; doi: 10.3389/fcell.2022.1105402

   The special issue: *https://www.frontiersin.org/research-topics/18812/epithelial-plasticity-and-complexity-in-development-disease-and-regeneration#overview*
6. Wang X, Ma Y, **Xu Q**, Shikovd AN, Pozharitskayae ON, Flisyukd EV, Liu M, Li H, Vargas-Murgag L, Duez P. Flavonoids and saponins: What have we got or missed? Phytomedicine. 2023; 109: 154580. (Google Scholar, 114 citations)
7. Feng Y, Chen Z-S, Xu H, **Xu Q**. Editorial: Medicinal plants in the treatment of gastrointestinal cancers: How can OMICS and other advanced approaches help in understanding their mechanisms of action? Front Pharmacol. 2022;13:1063915.

   The special issue: *https://www.frontiersin.org/research-topics/22409/medicinal-plants-in-the-treatment-of-gastrointestinal-cancers-how-can-omics-and-other-advanced-appro*
8. Shepherd A, Brunckhorst O, Ahmed K, **Xu Q**. Botanicals in the health and disease of the testis and male fertility: a scoping review. Phytomedicine. 2022;106:154398 (Google Scholar, 30 citations)
9. Anyu AT, Zhang W, **Xu Q**. Cultivated cordyceps: A tale of two treasured mushrooms. Chinese Medicine and Culture 2021;4:221-227 （won the 2nd Prize of the journal—see page 2) https://journals.lww.com/cmc/Fulltext/2021/10000/Cultivated_Cordyceps__A_Tale_of_Two_Treasured.4.aspx
10. ****Cockwell P,…, **Xu Q**. Renal Replacement Therapy for Critically Unwell Adult Patients: Guidelines for best practice and service resilience during COVID-19. https://renal.org/wp-content/uploads/2020/10/DRAFT-guidelines-RRT-for-Critically-Unwell-Adult-Patients.pdf
11. **Xu Q**. The renal collecting duct rises to the defence. Nephron 2019;143:148-152.
12. Holden F, Amin V, Kuek D, Kopp JB, Hendry BM and **Xu Q**. Taming the fire of nephrotoxic botanicals. World Journal of Traditional Chinese Medicine 2019;5:151-163. http://www.wjtcm.org/ch/reader/view_abstract.aspx?file_no=20180028&flag=1

- **highlighted by KCL:** https://www.kcl.ac.uk/news/news-article?id=3b151982-ff7d-4bb5-a457-e2031d45fe8b
- **highlighted by Kidney Research UK:** https://kidneyresearchuk.org/2019/06/17/researchers-call-for-international-collaboration-to-prevent-kidney-injury-caused-by-plant-based-drugs-or-food/
- **highlighted by Journal of Kidney Care:** https://doi.org/10.12968/jokc.2019.4.4.232

13. ** Feng Y, Yuen M-F, **Xu Q**, Wen X-Y, and Wang DQH. New exploration of Chinese herbal medicines in hepatology. Evid Based Complement Alternat Med. 2016;2016:3056438.
14. Bunel V, Qu F, Duez P, **Xu Q**. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1:47-66 (Google Scholar, 14 citations)
15. Williamson EM, Chan K, **Xu Q**, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, Stévigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. *Science* 2015, 347(6219 Suppl), S21-S23. (Google Scholar, 20 citations) https://www.science.org/doi/10.1126/science.347.6219.337-c
    - **This *Science* Special Feature article is a position paper of the Pharmacology & Toxicology Interest Group of the GP-TCM RA.**
16. **Xu Q**, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. *Science* 2014; 346 (6216 Suppl), S19-S20 (Google Scholar, 8 citations) https://www.science.org/content/resource/art-and-science-traditional-medicine-part-1-tcm-today---case-integration
    - **This *Science* Special Feature article was highlighted by a KCL press release and by Medical Xpress and myScience UK, etc.**
        - https://medicalxpress.com/news/2014-12-botanicals.html
        - https://www.myscience.uk/news/2014/the_hunt_for_botanicals-2014-kcl
17. Lu A, Zhang C, Verpoorte R, Robinson N, **Xu Q**. Creative and innovative good practice in traditional Chinese medicine clinical studies: Strategies for sustainable development. J Ethnopharmacol. 2014;155:1625-8.
18. *Pelkonen O, **Xu Q**, Fan T-P. Why is research on herbal medicinal products important and how can we improve its quality? Journal of Traditional and Complementary Medicine 2014;4:1-7. (Google Scholar, 137 citations) http://www.jtcm.org/temp/JtraditCompMed411-2619047_071630.pdf
19. ***Xu Q**, Bauer R, Hendry BM, Fan TP, Zhao ZZ, Duez P, Simmonds MSJ, Witt CM, Lu AP, Robinson N, Guo DA, Hylands PJ. The Quest for Modernisation of Traditional Chinese Medicine. BMC Complement Altern Med, 2013, 13:132 (Google Scholar, 298 citations)
20. ***Bauer R, Guo D-A, Hylands PJ, Fan TP, **Xu Q**. The Role of the GP-TCM Research Association to Modernization and Globalization of Traditional Chinese Medicine. In: Evandro Fei Fang, Tzi Bun Ng (Eds.) Antitumor Potential and other Emerging Medicinal Properties of Natural Compounds. Springer Science+Business Media Dordrecht, 2013, pp 377-385. ISBN: 978-94-007-6213-8 (Print) 978-94-007-6214-5 (Online) http://link.springer.com/chapter/10.1007/978-94-007-6214-5_25#page-1
21. ***Xu Q**, Qu F, Pelkonen O. Network Pharmacology and Traditional Chinese Medicine. In Sakagami H, ed. Alternative Medicine. ISBN 978-953-51-0903-7, Intech, 2012; pp277-297. (Semantic Scholar, 26 citations; 1 Highly Influential Citation)
22. **Xu Q** and Kopp JB. Retinoid and TGF-beta families: Crosstalk in development, neoplasia, immunity and tissue repair. Semin Nephrol, 2012; 32:287-294. (Google scholar, 44 citations)
23. *, **** Chan K, Shaw D, Simmonds MS, Leon CJ, **Xu Q**, Lu A, Sutherland I, Ignatova S, Zhu YP, Verpoorte R, Williamson EM, Duez P. Good practice in reviewing and publishing studies on herbal medicine, with special emphasis on traditional Chinese medicine and Chinese materia medica. J Ethnopharmacol. 2012;140:469-475 (Google Scholar, 260 citations)

24. *Buriani A, Garcia-Bermejo ML, Bosisio E, **Xu Q**, Li H, Dong X, Simmonds MS, Carrara M, Tejedor N, Lucio-Cazana J, Hylands PJ. Omic techniques in systems biology approaches to traditional Chinese medicine research: Present and future. J Ethnopharmacol. 2012;140:535-544 (Google Scholar, 246 citations)
25. *Uzuner H, Bauer R, Fan TP, Guo DA, Dias A, El-Nezami H, Efferth T, Williamson EM, Heinrich M, Robinson N, Hylands PJ, Hendry BM, Cheng YC, **Xu Q**. Traditional Chinese medicine research in the post-genomic era: Good practice, priorities, challenges and opportunities. J Ethnopharmacol. 2012;140:458-468 (Google Scholar, 108 citations)
26. *Pelkonen O, Pasanen M, Lindon JC, Chan K, Zhao L, Deal G, **Xu Q**, Fan TP. Omics and its potential impact on R&D and regulation of complex herbal products. J Ethnopharmacol. 2012;140:587-593 (Google Scholar, 85 citations)
27. Tejedor Garcia N, Garcia Bermejo L, Fernandez Martinez AB, Olmos Centenera G, Kumari R, **Xu Q**, Cheng X, Watson S, Lucio Cazaña FJ. MEDLINE-based assessment of animal studies on Chinese herbal medicine. J Ethnopharmacol. 2012;140:545-549 (Google Scholar 16 citations)
28. ****Xu Q** and Bauer R, co-eds. The GP-TCM Special Issue, Journal of Ethnopharmacology 2012; volume 140, issue 3. (**19 papers excluding the editorial cited more than 130 times each in average**)
29. ***Xu Q**, Wong YF, Qu S, Kong Q, Zhang XL, Liang XM, Hu Q, Noor M, Hendry BM. Knowledge-based discovery of anti-fibrotic and pro-fibrotic activities from Chinese materia medica. In Kuang X, ed. Recent Advances in Theories and Practice of Chinese Medicine, Intech, 2012, pp337-352. (**Book chapter reporting original data**; 16 Semantic Scholar Citations)
30. Uzuner H, Fan T-P, Dias A, Guo D-A, El-Nezami HS, **Xu Q**. Establishing an EU-China consortium on traditional Chinese medicine research. Chin Med. 2010;5:42. (Google Scholar, 33 citations)
31. Wong Y, Xu Q. Klotho ablation and premature aging: Is 1,25 dihydroxyvitamin D the key middleman? Kidney Int. 2009, 75:1137-1139 (Google Scholar 11 citations)
32. **Xu Q**, Konta T, Kitamura M. Retinoic acid regulation of mesangial cell apoptosis. Exp Nephrol. 2002;10:171-5. (Google Scholar, 29 citations)
33. Kitamura M, **Xu Q**, Nakayama K. Suppression of glomerular cell apoptosis by retinoic acid: Implication for therapeutic intervention in glomerulonephritis. Recent Res Devel Immunol. 2001;3:171-7.
34. ***Xu Q**, Lucio-Cazana J, Kitamura M, Ruan X, Fine LG, Norman JT. Retinoids in Nephrology: Promises and pitfalls. Kidney Int. 2004;66:2119-31. (**Perspective in Basic Science, including original research data**; Google Scholar, 97 citations)
35. Kitamura M, Ishikawa Y, Moreno-Manzano V, **Xu Q**, Konta T, Lucio-Cazana J, Furusu A, Nakayama K. Intervention by retinoic acid in oxidative stress-induced apoptosis. Nephrol Dial Transplant. 2002;17 Suppl 9:84-7 (Google Scholar 69 citations)

<u>30 published in Chinese</u>

36. 冯哲、杨聚荣主译、**徐启河**主审. 危重症肾脏病学手册（Koyner JL, Topf JM, Lerma EV. Handbook of Critical Care Nephrology. Wolters Kluwer; 2021)， 1-616 页. 人民卫生出版社, 2025 年 6 月 1 日。ISBN：9787117377454 。https://baike.baidu.com/item/危重症肾脏病学手册/66209267
37. 黄玉娇，张建军，靳凤玉，赵尹铭，郑佳，赵瑜，叶丹妮，李林泽，王淳，郭宝林，**徐启河**，王林元。新外来中药红色百金花的中药药性理论研究(A study on medicinal properties of *Centaurium erythraea* Rafn as a newly introduced traditional Chinese medicine)。环球中医药 2025 ;18(8) :1523-8.
38. 贾宇鑫，梁唯灿，何玉玉，付祥郴，王梓旭，修琳琳，郭宝林，**徐启河**，张建军，王淳 . 新外来中药互叶白千层的中药药性理论研究(On the integration of *Melaleuca alternifolia* (Maiden & Betche)

Cheel into traditional Chinese medicine as a new exotic medicinal resource.). 环球中医药 2025 ;18(8) :1545-52.

39. ***胡秦, 江丹, **徐启河**. 体外纤维化模型与中草药抗纤维化活性的再认识. 牛建昭，贲长恩主编. 器官纤维化基础及中医药防治.人民卫生出版社. 2008, pp678-pp682.（**作者兼编委；该书获选中华医药学会 2020 年度学术著作一等奖**）
40. ***陈香美，**徐启河**. 脂质代谢紊乱与慢性肾衰. 陈香美主编，徐启河副主编. 现代慢性肾衰治疗学. 人民军医出版社 2001;pp14-18.
41. ***徐启河**. 血液净化患者的钙磷代谢问题. 陈香美主编，徐启河副主编. 现代慢性肾衰治疗学. 人民军医出版社 2001;P250-254.
42. ***徐启河**. 透析相关淀粉样变性. 陈香美主编，徐启河副主编. 现代慢性肾衰治疗学. 人民军医出版社 2001;P255-257.
43. *,**陈香美主编，**徐启河**副主编. 现代慢性肾衰治疗学. 人民军医出版社 2001 (ISBN 7-80157-096-0) (Google Scholar: 588 citations)
44. *陈香美, 喻陆, **徐启河**. 肾脏细胞的活化与慢性进展性肾病. 中华肾脏病杂志, 2000, 16(1):3 (Baidu Scholar 84 citations)
45. * 陈香美, **徐启河**. 肝素治疗肾小球疾病的机理研究进展. 中华肾脏病杂志. 1998;14:331-333. (Baidu Scholar: 221 citations)
46. **徐启河**, 陈香美. 细胞外基质降解酶与肾脏. 国外医学:泌尿系统分册. 1997;17:25-27.
47. ***徐启河**. 肾脏病与钙磷代谢异常. 陈香美主编. 实用肾脏病学. 第一版. 北京医科大学中国协和医科大学联合出版社, 1995: P39-45.
48. ***徐启河**. 血尿. 陈香美主编. 实用肾脏病学. 第一版. 北京医科大学中国协和医科大学联合出版社,1995: P306-314.
49. ***徐启河**.肾脏病的抗凝治疗. 陈香美主编. 实用肾脏病学. 第一版. 北京医科大学中国协和医科大学联合出版社,1995: P39-45.
50. **徐启河**. 细胞因子与急性肾功能衰竭. 国外医学： 泌尿系统分册. 1994;14:20-24.
51. **徐启河**. 血尿的再认识. 临床荟萃. 1994; 9:4-5.
52. **徐启河**, 刘平. 肾性骨病. 中级医刊. 1993; 28:10-11.
53. ***徐启河**, 李惊子, 王海燕. 脂质代谢紊乱与进行性肾损伤. 国外医学（内科学分册）1992, (2):73-76. (Baidu Scholar, 45 citations)
54. **徐启河**, 刘平. 罗钙全在慢性肾衰患者的应用. 实用内科杂志. 1992, 12(5):275-276.
55. **徐启河**, 郑桂风. 高血压个体化阶梯疗法的理论与实践. 临床荟萃. 1992, 7(7):314-317.

Peer-reviewed primary research papers (n=55)

29 published in English:

56. Zhuo F-F, Guo Q, Zheng Y-Z, Liu T-T, Yang Z, **Xu Q-H**, Jiang Y, Liu D, Tu P-F, Zeng K-W. Photoaffinity labelling-based chemoproteomic strategy reveals RBBP4 as a cellular target of protopanaxadiol against colorectal cancer cells. ChemBioChem 2022; e202200038.

57. Zhou S, Yin X, Yuan J, Liang Z, Song J, Li Y, Peng C, Zhao ZZ, Hylands PJ and **Xu Q**. Antifibrotic activities of Scutellariae Radix extracts and flavonoids: comparative proteomics reveals distinct and shared mechanisms. Phytomedicine. 2022;100:154049.

58. Chen X, Ma J, He Y, Xue J, Song Z, **Xu Q**, Lin G. Characterization of liver injury induced by a pyrrolizidine alkaloid in rats. Phytomedicine 2021;89:153595 (Co-corresponding author)

59. § Zhou S, Yin X, Mayr M, Noor M, Hylands PJ and **Xu Q**. Proteomic landscape of TGF-β1-induced fibrogenesis in renal fibroblasts. Sci Rep 2020;10:19054 (Google Scholar, 42 citations)

60. Papadimitriou A, Romagnani P, Angelotti ML, Noor M, Corcoran J, Raby K, Wilson PD, Li J, Fraser D, Piedagnel R, Hendry BM and **Xu Q**. Collecting duct cells show differential retinoic acid responses to acute versus chronic kidney injury stimuli. Sci Rep 2020;10:16683.

61. Zhang Y, Sun L, Zhou S, **Xu Q**, Xu Q, Liu D, Liu L, Hu R, Quan S, Xing G. Intrarenal Arterial Lesions Are Associated with Higher Blood Pressure, Reduced Renal Function and Poorer Renal Outcomes in Patients with IgA Nephropathy. Kidney Blood Press Res. 2018 Apr 23;43(2):639-650 (Google Scholar, 46 citations)

62. *Zhang Y, Yan X; Zhao T, **Xu Q**; Peng Q; Hu R; Quan S; Zhou Y, Xing G. Targeting C3a/C5a receptors inhibits human mesangial cell proliferation and alleviates IgA nephropathy in mice. Clin Exp Immunol. 2017;189:60-70. (Google Scholar, 77 citations)

63. Wang N, **Xu Q**, Tan HY, Hong M, Sha L, Yuen M-F and Feng Y. Berberine inhibition of fibrogenesis in a rat model of liver fibrosis and in hepatic stellate cells. Evid Based Complement Alternat Med. 2016;2016:8762345. (Semantic Scholar 39 citations)

64. *Zeng L, Wang G, Ummarino D, Margariti A, **Xu Q**, Xiao Q, Wang W, Zhang Z, Yin X, Mayr M, Cockerill G, Li JY, Chien S, Hu Y, Xu Q. Histone deacetylase 3 unconventional splicing mediates endothelial-to-mesenchymal transition through transforming growth factor β2. J Biol Chem. 2013;288:31853-66. (Google Scholar, 48 citations)

65. Rankin AC, Hendry BM, Corcoran J, **Xu Q**. An *in vitro* model for the profibrotic effects of retinoids: Mechanisms of action. Br J Pharmacol. 2013;170:1177-89 (Google Scholar, 31 citations)

66. Wong YF, Wilson PD, Unwin RJ, Norman JT, Arno M, Hendry BM, **Xu Q**. Retinoic acid receptor-dependent, cell-autonomous, endogenous retinoic acid signalling and its target genes in mouse collecting duct cells. PloS One 2012, 7: e45725. (Google scholar, cited by 20)

67. Wong YF, Kopp JB, Roberts C, Scambler PJ, Abe Y, Rankin AC, Dutt N, Hendry BM, **Xu Q**. Endogenous retinoic acid activity in principal cells and intercalated cells of mouse collecting duct system. PloS One. 2011;6:e16770. (Google Scholar, 20 citations)

68. **Xu Q**, Hendry BM, Maden M, Lu H, Wong YF, Rankin AC, Noor M, Kopp JB. Kidneys of Alb/TGF-beta1 transgenic mice are deficient in retinoic acid and exogenous retinoic acid shows dose-dependent toxicity. Nephron Exp Nephrol. 2010;114:e127-e132.

69. *Hu Q, Noor M, Wong YF, Hylands PJ, Simmonds MSJ, Xu Q, Jiang D, Hendry BM, **Xu Q**. *In vitro* anti-fibrotic activities of herbal compounds and herbs. Nephrol Dial Transplant. 2009; 24:3033-3041. (Google Scholar, 139 citations)

70. ***Xu Q**, Norman JT, Shrivastav S, Lucio-Cazana J, Kopp JB. *In vitro* models of TGF-β1 induced fibrosis suitable for high-throughput screening of anti-fibrotic agents. Am J Physiol Renal Physiol. 2007; 293: F631-F640. (Google Scholar, 176 citations)

71. Alique M, Lucio-Cazana FJ, Moreno V, **Xu Q**, Konta T, Nakayama K, Furusu A, Sepulveda JC, Kitamura M. Upregulation of cyclooxygenases by retinoic acid in rat mesangial cells. Pharmacology. 2007;79:57-64.

72. *Furusu A, Nakayama K, **Xu Q**, Konta T, Kitamura M. MAP kinase-dependent, NF-kappaB-independent regulation of inhibitor of apoptosis protein genes by TNF-alpha. J Cell Physiol. 2007;210:703-710. (Google Scholar, 34 citations)

73. Alique M, Moreno V, Kitamura M, **Xu Q**, Lucio-Cazana FJ. Kinase-dependent, retinoic acid receptor-independent up-regulation of cyclooxygenase-2 by all-*trans* retinoic acid in human mesangial cells. Br J Pharmacol. 2006; 149:215-25

74. ***Xu Q,** Konta T, Nakayama K, Furusu A, Moreno-Mazano V, Lucio-Cazana J, Ishikawa Y, Fine LG, Yao J, Kitamura M. Cellular defense against H_2O_2-induced apoptosis via MAP kinase-MKP-1 pathway. Free Radic Biol Med. 2004; 36: 985-93. (Google Scholar, 100 citations)

75. *Moreno-Manzano V, Mampaso F, Sepulveda-Munoz JC, Alique M, Chen S, Ziyadeh FN, Iglesias-de la Cruz MC, Rodriguez J, Nieto E, Orellana JM, Reyes P, Arribas I, **Xu Q**, Kitamura M, Lucio Cazana FJ. Retinoids as a potential treatment for experimental puromycin-induced nephrosis. Br J Pharmacol. 2003;139:823-31 (Google Scholar, 83 citations)

76. ***Xu Q**, Konta T, Furusu A, Nakayama K, Lucio-Cazana J, Fine LG, Kitamura M. Transcriptional induction of mitogen-activated protein kinase phosphatase 1 by retinoids. Selective roles of nuclear receptors and contribution to the antiapoptotic effect. J Biol Chem. 2002;277:41693-700. (Google Scholar, 86 citations)

77. Furusu A, Nakayama K, **Xu Q**, Konta T, Sugiyama H, Kitamura M. Expression, regulation, and function of inhibitor of apoptosis family genes in rat mesangial cells. Kidney Int. 2001;60:579-86.

78. *Nakayama K, Furusu A, **Xu Q**, Konta T, Kitamura M. Unexpected transcriptional induction of monocyte chemoattractant protein 1 by proteasome inhibition: involvement of the c-Jun N-terminal kinase-activator protein 1 pathway. J Immunol. 2001;167:1145-50. (Google Scholar, 100 citations)

79. *Konta T, **Xu Q**, Furusu A, Nakayama K, Kitamura M. Selective roles of retinoic acid receptor and retinoid X receptor in the suppression of apoptosis by all-*trans*-retinoic acid. J Biol Chem. 2001;276:12697-701. (Google Scholar, 81 citations)

80. *Lucio-Cazana J, Nakayama K, **Xu Q**, Konta T, Moreno-Manzano V, Furusu A, Kitamura M. Suppression of constitutive but not IL-1beta-inducible expression of monocyte chemoattractant protein-1 in mesangial cells by retinoic acids: intervention in the activator protein-1 pathway. J Am Soc Nephrol. 2001;12:688-94. (Google Scholar, 35 citations)

81. **Xu Q**, Chen X, Fu B, Ye Y, Yu L, Wang J, Li W, Cheng Q. Integrin alpha v beta3-RGDS interaction mediates fibrin-induced morphological changes of glomerular endothelial cells. Kidney Int. 1999;56:1413-22 (Baidu Scholar, 32 citations)

82. Chen X, He Q, Liu W, **Xu Q**, Ye Y, Fu B, Yu L. AP-1 mediated signal transduction in thrombin-induced regulation of PAI-1 expression in human mesangial cells. Chin Med J (Engl). 2000;113:514-9.

83. Deng Y, Chen X, Liao H, Ye Y, **Xu Q**, Yu L. Cloning and expression of human PAI-1 in glomerular mesangial cells. Science in China, Series C (English Edition). 1998;28:179-185.

84. *Chen X, Liu S, Ye Y, **Xu Q**. Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with the clinico-pathological manifestations in immunoglobulin A nephropathy patients. Chin Med J (Engl). 1997;110:526-9. (Baidu Scholar: 43 citations)

<u>26 published in Chinese</u>

85. 魏日胞, 龙丽娟, 蔡广研, **徐启河**, 陈香美. 老年慢性肾衰病人颈动脉内-中膜厚度的变化及其相关因素研究. 解放军医学杂志, 2002,27(5):447-449.

86. 高桂凤, 陈振玉, **徐启河**, 陈香美. 结核病相关 IgA 肾病 1 例. 军医进修学院学报. 2001(4):290.

87. **徐启河**, 陈香美, 傅博,等. 整合素αvβ3-RGDS 位点相互作用介导纤维蛋白所致的肾小球内皮细胞表型变化. 解放军医学杂志. 1999, 24(3): 160-164.

88. *__徐启河__, 陈香美,张颖,师锁柱,文载律. 5/6 肾切除大鼠模型尿纤溶酶原激活物活性的动态观察. 解放军医学院学报, 1999, 20(2):106-108. (Baidu Scholar, 32 citations)

89. **徐启河**, 陈香美, 傅博, 等. 纤维蛋白对肾小球内皮细胞表达胞间粘附分子-1 的影响及其机制探讨. 解放军医学杂志. 1999, 24(3):164-167.

90. *陈香美, 傅博, 叶一舟, 田巍, **徐启河**,王建中， 韩玉珉. 凝血酶介导肾小球系膜细胞细胞间粘附分子 1 表达上调及水蛭素的阻断作用. 中华肾脏病杂志. 1998;14:211-214. (Baidu Scholar: 59 citations)

91. *陈香美, **徐启河**, 张颖. 重组水蛭素延缓部分肾切除大鼠慢性进行性肾损伤的初步研究. 中华内科杂志 1998;37(12):838-839. (Baidu Scholar: 93 citations)

92. **徐启河**, 刘平， 李惊子， 姜筠. 肾骨胶囊对血液透析患者钙磷代谢的影响. 解放军医学院学报 1997, 18(3):210-212.

93. **徐启河**, 陈香美, 傅博. 凝血酶对肾小球内皮细胞和系膜细胞增殖的影响. 解放军医学杂志 1997, 22(6):440-441

94. **徐启河**， 陈香美. 凝血酶导致肾小球内皮细胞增殖与脱壁机制的研究. 中华内科杂志 1997; doi: 10.1007/BF02951625 (Baidu Scholar: 31 citations)

95. 张颖, 陈香美, **徐启河**. 流式尿沉渣自动分析仪检测肾小球性血尿的鉴别诊断意义. 中华内科杂志. 1997; 36(5):340. (Baidu Scholar: 28 citations)

96. 杨筱伟, 陈香美, **徐启河**, 秦晓新, 陈振玉, 师锁柱. 低分子量肝素对增殖性肾炎的疗效观察. 中华内科杂志 1997;36(11): 731-735 (Google Scholar: 63 citations)

97. **徐启河**, 陈香美, 于力方. IgA 肾病患者肾小球内纤维蛋白相关抗原沉积的意义. 中华内科杂志. 1996;35:140-41. (Baidu Scholar: cited by 23)

98. 魏日胞, **徐启河**, 鲍洪雅, 陈香美. 第 208 例——痰中带血,发热,进行性少尿. 中华内科杂志. 1996;35:142-143.

99. 魏日胞, **徐启河**, 朱宁, 鲍洪雅, 刘述文,廖洪军, 陈振玉. 1 例重症 Goodpasture 病的诊治. 军医进修学院学报. 1996;17(2):104-6.

100. *陈香美, 师锁柱, 于力方, **徐启河**. 纤维蛋白原相关抗原沉积与肾小球硬化的关系探讨. 中国病理生理杂志. 1996; 12:202-205. (Baidu Scholar, 35 citations)

101. 王建中, 陈香美, **徐启河**, 傅博, 于力方, 廖洪军. 肾小球内皮细胞凋亡与细胞外基质表达. 解放军医学杂志. 1996;121:423-425.

102. 师锁柱, 陈香美, 于力方, 徐启河. IgA 肾病患者肾间质 T 淋巴细胞亚群变化的意义. 解放军医学杂志. 1995;20:193-195.

103. 陈香美, 徐启河. 细胞粘附分子在狼疮性肾炎及膜增殖性肾炎肾组织中的表达. 中华病理学杂志, 1995;24(3):149-51. / Abstract in English. Kidney Int. 1995;48:596.

104. 于力方, 陈香美, 徐启河. 以激光扫描共聚焦显微镜三维重建肾小球系膜细胞. 中华医学检验杂志, 1995, 18(4): 229-231 / Abstract in English. Kidney Int. 1995;48:600-601.

105. 陈香美, 徐启河, 段永刚, 陈中华. 狼疮性肾炎患者血清抗肾小球内皮细胞抗体变化及其临床意义. 中华内科杂志.1995; 34(6): 411-412; Kidney Int. (Abstract in English). 1995;48: 622.

106. **徐启河**, 刘平, 李惊子, 黄颖, 冷炜, 韩秀菊, 申洪征. 三种甲旁腺激素测定在血液透析患者的意义. 北京医科大学学报 1994;26(4):287-288,290.

107. **徐启河**, 陈香美, 陈振玉. 第 191 例——多神经炎、器官肿大、阳痿、高γ球蛋白血症、皮肤色素沉着、蛋白尿. 中华内科杂志. 1994;33(8):571-573.

108. **徐启河**,刘平,姜筠, 吴希云, 黄颖. 钙与血透患者的甲旁腺功能. 肾脏病与透析肾移植杂志. 1993;1:28-31.

109. **徐启河**, 刘平, 姜筠. 去屏纸包片与骨密度测定诊断血液透析患者的肾性骨病. 透析与人工器官杂志 1993; 4:15-17.

110. 刘平, **徐启河**, 王国苏, 吴希云, 王辉元. 血透患者钙磷代谢紊乱的临床研究. 实用内科杂志. 1993; 13:272-3.

DISSEMINATION & OUTREACH: ARTICLES

10 published in English

109. Reports on the first Honorary Advisory Board Meeting and the Inaugural Forum of the King's Centre for Integrative Chinese Medicine. GP-TCM RA Newsletter, Jan.-Feb. 2025. https://www.gp-tcm.org/wp-content/uploads/2025/02/GP-TCM-RA-Newsletter-January-February-2025.pdf

110. **Xu Q**. A Brief History of the *GP-TCM RA Newsletters*: It all began with the 23 humble "oldsletters". *GP-TCM RA Newsletter*, Jan. 2020.
http://www.gp-tcm.org/wp-content/uploads/2022/04/Jan-2020-NL-final-R1.pdf

111. **Xu Q**. Professor Peter Hylands' contributions to integrative Chinese medicine. *GP-TCM RA Newsletter*, Oct. 2019.
http://www.gp-tcm.org/wp-content/uploads/2022/04/October-2019-GP-TCM-RA-NL.pdf

112. **Xu Q.** Let traditional wisdom inspire: a nephrologist's view. *GP-TCM RA Newsletter*, Aug. 2019
http://www.gp-tcm.org/wp-content/uploads/2022/04/August-2019-GP-TCM-RA-NL.pdf

113. **Xu Q**. *In memoriam* Peter John Hylands (1946-2019). *GP-TCM RA Newsletter*, Jun. 2019
http://www.gp-tcm.org/wp-content/uploads/2022/04/Jun-2019-GP-TCM-RA-NL.pdf

114. Holden F, Amin V, Kuek D, Kopp JB, Hendry BM and **Xu Q**. Taming the fire of nephrotoxic botanicals. *GP-TCM RA Newsletter*, Mar. 2019.
http://www.gp-tcm.org/wp-content/uploads/2019/03/Mar-2019-GP-TCM-RA-NL.pdf

115. **Xu Q**, Hylands PJ. Integrative Chinese Medicine. *GP-TCM RA Newsletter*, Apr. 2017.
http://www.gp-tcm.org/wp-content/uploads/2022/04/GP-TCM-RA-NL-28-3-2017-compressed.pdf

116. **Xu Q**, Duez P, Chang YS. Our Journey Continues: Welcome to the GP-TCM RA Newsletters! *GP-TCM RA* Newsletter, Mar 2017.
http://www.gp-tcm.org/wp-content/uploads/2022/04/Feb-Mar-2017-GP-TCM-RA-NL.pdf

117. Fan TP, **Xu Q**. Looking Forward to the Future of the GP-TCM RA. *GP-TCM RA Newsletter*, Dec. 2016.http://www.gp-tcm.org/wp-content/uploads/2022/04/NL-Christmas-2016-v6.pdf

118. **Xu Q**. Simple and passionate. *GP-TCM RA Newsletter*, Nov. 2014.
http://www.gp-tcm.org/wp-content/uploads/2022/04/November-2014-NL-v4.pdf

3 published in English

119. **徐启河**. 中医药助力英国抗疫:机遇与挑战。英伦大叔微信公众号。2020 年 5 月 5 日：https://mp.weixin.qq.com/s/VLA02U3yB7FXDB-BqrlT5Q

120. **徐啟河**. 中醫藥助力英國抗疫:機遇與挑戰。現代化中醫藥國際協會成立二十週年紀念特刊。2020 年 8 月，81-3 页：https://mcmia.org/wp-content/uploads/2021/12/MCMIA-Album-20.pdf

121. **徐启河. 伦敦大学学院中国学生学者联合会举行中医在英国学术研讨会. 人民日报海外版 2000 年 8 月 21 日第三版.**

DISSEMINATION & OUTREACH: OTHER ACTIVITIES

2025	Wrote to Mr Dawn Butler, Member of Parliament, and invited him to attend an event organised by the Kidney Research UK and support kidney research (26th April).
2025	The video recording of the Inaugural Forum of the King's CICM 2.0 initiative published via Youtube: https://www.youtube.com/watch?v=URMN4feJ7zI
2024	The Handbook of the King's CICM 2.0 initiative and our action plan, including a full list of our Honorary Advisors, was published on the CCMUK website: https://ccmuk.org/wp-content/uploads/2024/12/CICM-call-for-consultation-v36.pdf
2024	中国新闻网报道"伦敦国王学院整合中医药中心项目启动": https://news.qq.com/rain/a/20241010A08QBZ00
2023	徐启河. 中草药相关的国际标准、规范与指南. 世界传统医药论坛学术讲座. 2023-6-25 孟凡毅、赵凯存、徐启河. 谈中药的毒性与预防. 英伦杏林医话第 25 期. 2023-4-28：https://www.bilibili.com/video/BV1UV4y1R7fW/?vd_source=3a0871eaade596f6b755a1c0c962346a
2022	赵凯存、马玉玲、唐铁军；客串：徐启河. 中药现代药理研究的临床意义. 英伦杏林医话第 18 期. 8 月 28 日. https://m.bilibili.com/video/BV1XT411F77o https://m.youtube.com/watch?v=4j8vM1Ra6Gk
2022	唐铁军、徐启河、王娴. 中西医能否结合？怎样结合？ 英伦杏林医话第 12 期。2 月 26 日。https://m.bilibili.com/video/BV1TP4y1c7sk https://www.youtube.com/watch?v=lkirXaUxoC4
2021	The PKD Charity UK published a blog introducing my research that first uncovers a link between vitamin A and ARPKD, 18th August 2021: https://pkdcharity.org.uk/news-events/blogs/44-research-uncovers-links-between-vitamin-a-and-arpkd
2020	KCL news, 14th Dec. 2020, entitled "King's academic awarded for significant contribution to Chinese medicine": https://www.kcl.ac.uk/news/kings-academic-awarded-for-significant-contribution-to-chinese-medicine
2020	Member of the Joint Working Group for AKI in Critical Care of the Renal Association UK chaired by Paul Cockwell and Jon Murray.
2019	Wrote to WHO Secretary-General on 16th August 2019 to propose WHO leadership in integrating botanical pharmacovigilance into the existing pharmacovigilance network worldwide.
2019	Wrote to Principal of King's College London on 13th August 2019, offering 9 pieces of suggestions on protecting Institute of Pharmaceutical Science and on integrating

annual professional development reviews with Strategic Vision 2029 to promote cost-effective research, disruptive research, enabling, service, wellbeing and learning.

2019 In an article by Laura Broadwell, entitled *Can Chinese Herbs Reduce Need for Rx Meds?,* MEDshadow 14th July 2019, my view on the importance of authentication and quality control of herbal materials in scientific research was quoted: https://medshadow.org/can-chinese-herbs-reduce-need-for-rx-meds/

2019 Interviewed by CNN in an article, published on 21st June 2019 entitled "Chinese medicine: The next step in cancer recovery?"

https://edition.cnn.com/2019/06/19/health/chinese-modern-medicine-cancer-hong-kong-intl/index.html

2019 Kidney Research UK press release by Maria Thompson: "Researchers call for international collaboration to prevent kidney injury caused by plant-based drugs or food". 17th June 2019. https://www.kidneyresearchuk.org/news/researchers-call-for-international-collaboration-to- prevent-kidney-injury-caused-by-plant-based-drugs-or-food?

2019 KCL press release by Hannah Forrest: "Researchers call for international collaboration to prevent kidney injury caused by botanicals". Dr Qihe Xu, the lead author, concluded: "Botanicals, just like any other drugs, are like fire. If we know their effects and mechanisms of action and use them properly, they can benefit us and become an important part of our civilisation. Otherwise, we would miss the opportunities they offer and could even be harmed. Given the complexity of botanicals and weakness in research so far, I'd cordially invite investment and collaborations in this important research field"

https://www.kcl.ac.uk/news/news-article?id=3b151982-ff7d-4bb5-a457-e2031d45fe8b

2019 On 28th April 2019, proposed that the post-Brexit UK takes a lead in collaboration with China in TCM research, in a letter to Prof. Sir Adrian Smith, who has been commissioned by Chris Skidmore, Minister of State for Universities and Science to provide independent advice to UK government on the design of future UK funding schemes for international collaboration, innovation and research.

2016 Commented on the Chinese parliament's website on (i) the objectives of legislation of TCM in China, (ii) the definition of integrative Chinese medicine and (iii) the responsibilities and rights of China's State Administration of TCM in international cooperation for TCM-related legislation and scientific and technological cooperation: www.cpn.gov.cn

2015 In support of the "Science is Vital" Campaign, wrote a postcard to Chancellor of the Exchequer and Tatton MP George Osborne to ask increase public funding into research towards 3%.

2015 As Co-Director of King's Centre for Integrative Chinese Medicine, Chairman of the Steering Committee and Coordination Office of the FP7 GP-TCM project, nominated Professor Youyou Tu, the first Chinese Nobel laureate in physiology or medicine and the first citizen of the People's Republic of China to receive the Nobel Prize in natural sciences, for an Honorary Doctor's Degree of KCL: http://www.bbc.co.uk/news/blogs-china-blog-34451386

2015-2017 Advisory Board Member, the 7th Executive Committee of the Federation of UK Guangdong Chinese. http://www.fgd.org.uk/cn/index.asp

2015 King's Brand Ambassador, KCL.

2014 King's press release on my *Science* special feature article on the importance of the "double-edged sword" effect of botanicals in the prevention and treatment of fibrotic diseases (published on 19th December 2014 and reported on the front pages of numerous public media such as SciGuru.org, medicalxpress.com, myscience.org.uk, topnews-uk.com, cn.biodips.com, ewww.scicentral.com, as well as the homepages of King's and the University of London).

https://medicalxpress.com/news/2014-12-botanicals.html

https://www.myscience.uk/news/2014/the_hunt_for_botanicals-2014-kcl

2014 On 16th December 2014, when commenting on main milestones of International Partnerships in 2014, Vice-Principal (Health) emphasised King's progressing relationship with the Peking University Health Science Centre (PUHSC) and highlighted "traditional Chinese medicine" as one of the 5 areas to forge closer links and to explore joint funding opportunities.

2014 Interviewed by *The Wall Street Journal* on 30th October 2014. The report was published on 3rd November 2014, entitled *A Push to Back Traditional Chinese Medicine with More Data: Researchers Marry Modern Analytical Techniques to Centuries-Old Theories on What Makes People Sick.*

http://online.wsj.com/articles/a-push-to-back-traditional-chinese-medicine-with-more-data-1415036616

Also reported by *Fox News*:

http://www.foxnews.com/health/2014/11/04/researchers-push-to-back-traditional-chinese-medicine-with-more-data/

2014 The FP7 GP-TCM project was chosen as a case for study of "Network Analysis of FP7 Participation" by Oxford Research, an international agency funded by the European Commission because the project '*has strongly contributed to international research relations between the EU and third countries*' in the HEALTH sub-programme. Dr. Qihe Xu, the FP7 GP-TCM Coordinator and the GP-TCM RA Vice President, Professor Rudolf Bauer, Founding President of GP-TCM RA, and GP-TCM RA BoD members Prof. Peter Hylands, Prof. Rob Verpoorte and Prof. Pierre Duez received interviews, leading to a 10-page report to the commission by the agency. The report says, "*Interviews stated that GP-TCM had lowered the barriers for collaboration between EU and China and the GP-TCM Research Association is instrumental to further lowering the barriers.*"

2014 Interviewed by *China Radio International*, entitled "TCM's Overseas Development"

http://english.cri.cn/7146/2014/04/23/3621s823449.htm

2013 GP-TCM a success, says Brussels:

http://www.manufacturingchemist.com/news/article_page/Chinese_medicine_research_programme_a_success_says_Brussels/92322

2013 Member, the Conservative Friends of the Chinese, UK

http://www.conservativefriendsofthechinese.co.uk/

2013 Organised the discussion among PIs in 9 UK institutions, GP-TCM Research Association Board of Directors, PIs in other 9 EU member states and coordinated official input proposal to Horizon 2020 entitled *Traditional Chinese Medicine: Safety Issues and Chronic Disease.*

2013 Informed regulators and pharmacovigilance organisations in the UK (HMRA) and China (Centre for Drug Re-evaluation, National Centre for Monitoring Adverse Drug Reactions, State Food and Drug Administration) about the potential profibrotic activities of Chuanwutou (Main roots of *Aconitum carmichaeli* Debx.) and Yimucao (rootless plants of *Leonurus japonicas* Houtt.).

2013- King's Advocate, KCL.

2012 Signed the *no-cuts-on-research.eu petition*, which follows up on an open letter, signed by 42 European Nobel laureates, published in newspapers around Europe.

http://www.no-cuts-on-research.eu/index.php?file=danke.php

2012 In October, through UK Research Office (UKRO), FP7 National Contact Points and Research Offices of other European member states at the Commission, submitted a follow-up report proposing to list traditional Chinese medicine research as a priority funding area in EU-China collaborations under the Health Theme of Horizon 2020. The follow-up report was signed by 15 principal investigators based in 9 UK institutions and was seconded by 9 additional EU member states and Associated Countries.

2012 Submitted a proposal to the Wellcome Trust, on behalf of the FP7 GP-TCM Consortium, to revisit the Trust's 10-year-old policy on complementary and alternative medicine.

2012 In May, through UKRO, the UK's National Contact Points and Research Offices of other European member states at the Commission, proposed to list traditional Chinese medicine research as a priority funding area in EU-China collaborations under the Health Theme of Horizon 2020. The proposal was signed by 15 principal investigators based in 9 UK institutions and was seconded by 9 additional EU member states and Associated Countries.

2012 Modern medicine can learn from traditional practices, says European Commission: https://cordis.europa.eu/article/id/91212-modern-medicine-can-learn-from-traditional-practices

2012 Interviewed by Phoenix TV on the FP7 GP-TCM project, its Final Conference and Congress, as well as the newly founded GP-TCM Research Association.

http://www.youtube.com/watch?v=kQ4QJRfLmqk&feature=youtube_gdata_player

2012 Organised the publicity of the GP-TCM Research Association.

http://www.healthcanal.com/alternative-therapies/28480-Traditional-Chinese-medicine-research.html

http://www.gp-tcm.org/2012/04/about-association/

2012 KCL press release: King's scientists led founding new research association

http://www.kcl.ac.uk/newsevents/news/newsrecords/2012/04April/New-association-for-good-practice-in-Chinese-medicine-research.aspx

2012 Organised the FP7 GP-TCM Grand Issues Survey.

http://www.gp-tcm.org/2011/08/%E2%80%9Cgrand-priorities-challenges-and-opportunities%E2%80%9D-survey/

2011 As Chairman of the Steering Committee and Coordination Office of the FP7 GP-TCM project, successfully nominated Co-Chairman of the Advisory Board of the GP-TCM project, Professor Yung-Chi Cheng, Yale University, for the 1st Cheung On Tak International Award for Outstanding Contribution to Chinese Medicine: http://scm.hkbu.edu.hk/en/cm-award/first/

2011 Sponsored by UK Department for Business, Innovation and Skills, toured science parks, universities and research institutes in Shanghai to disseminate my research on anti-fibrotic herbs and the outcomes of my FP7 GP-TCM project.

Interviewed by *Shanghai Science & Technology Post*, in which I introduced the development of TCM and TCM research in Europe in the past 12 years and forecast of the coming 12 years. The report was published in Chinese （陈怡。中医药 越研究越有味道——访欧盟中医药现代化研究协作组首席科学家徐启河博士。 科技报 2011 年 11 月 04 日）：https://www.shkjb.com/content.html?id=152271

2011 GP-TCM joint meeting with The EDQM European Pharmacopoeia – Traditional Chinese Medicine (TCM) Working Party Members, Strasbourg, France.

2011 Interviewed by CAMbrella, an FP7 consortium, highlighting the FP7 GP-TCM project as reported in the CAMbrella website:

http://www.cambrella.eu/home.php?il=155&l=deu

2011 Press release of the European Commission: EU-Sino study spotlights traditional Chinese medicine: https://cordis.europa.eu/article/id/36108-harmonising-eu-research-on-traditional-chinese-medicines

2010 In support of the "Science is Vital" Campaign, wrote to Member of Parliament, Mr. Barry Gardener, to urge the government to restrain from cutting research funding. Barry wrote on my behalf to the Rt. Hon David Willetts MP, Minister for Universities and Science, who met "Science is Vital" Representatives at the end of 2010 and replied in Feb. 2011, promising to protect funding for science and research

programmes in cash terms, in a ring-fenced budget. Ref No. Gardener letter: RM/ XU 01001 / 01110407; Ref. No. Willetts letter RM/232644.

2010 Led the submission of a one-pager proposal for the Chinese government to develop a "China-EU TCM Research Seeding Fund", which was endorsed by 60 principal investigators based in 13 countries and areas. This proposal was welcomed by the Chinese government and will be taken as an important reference when discussing with the European Commission for future international collaborations, including the Framework Programme 8, starting from 2014. The Chinese State Administration of TCM has selected EU has a priority support region in the coming 5 years.

2009 KCL press release: €1 million EU funding for Chinese medicine research, which has been disseminated through many online media.

http://www.eurekalert.org/pub_releases/2009-05/kcl-kcw050509.php

2007 Nominated for the 2007 National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) Prize for the development of innovative in vitro model-based assays for screening anti-fibrotic activities, entitled "In vitro models of TGF-beta-induced fibrosis suitable for high-throughput screening of antifibrotic agents". By invitation, the work was exhibited at the British Parliament (House of Commons) to promote the 3Rs.

2002- Founding Advisory Board Member, the Federation of UK Guangdong Chinese. http://www.fgd.org.uk/cn/index.asp

INVITED TALKS & LECTURES

2025 **Invited keynote speech:** Integrative Chinese Medicine: An innovative approach to addressing unmet medical needs. Dutch Traditional Chinese Medicine Congress "Building Bridges – The Path to Integrative Medicine", the Dutch Traditional Chinese Medicine Association Zhong (also known in Dutch as NVTCG ZHONG), The Netherlands, 1st-2nd November 2025.

Invited talk: scRNA-seq locating **A**LDH1A2-mediated retinoic acid synthetic pathway to glomerular Parietal Epithelial Cells (**PEC**) and mapping *ALDH1A2* genetic VArianTs to phenotypes in pAtients with nephRotic syndrome (AVATAR). UK Kidney Week June 2025, Bournemouth, UK.

2024 **Keynote speech:** Integrative Chinese Medicine: An innovative approach to addressing unmet medical needs. Chinese Acupuncture and Herbal Medicine Alliance Annual Meeting, Heathrow, UK. 17th November 2024.

Keynote speech, international meeting: International Standards & Guidelines in Integrative Medicine Research & Development. The Fourth International Forum of *Integrative Medicine in Nephrology and Andrology (IMNA)* on Clinical Research and Transformation of Traditional Chinese Medicine, Beijing, China, 26th October 2024

Invited talk: Fibrometabolism: Targeting metabolism to develop safe and cost-effective antifibrotics. School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China, 25th October 2024.

Invited talk: Integrative Chinese Medicine: An innovative approach to addressing unmet medical needs. School of Pharmacy, Beijing University of Chinese Medicine, Beijing, China, 24th October 2024.

Keynote speech, international meeting: The Quest for Modernisation of Chinese Medicine: International Standards and Guidelines in the Era of Digital Intelligence. Mianyang, Sichuan, China, 1st June. 2024.

Invited talk: Towards scarless repair: Fibrosis is a metabolic disorder that could be prevented by metabolic intervention. Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China, 20th June. 2024.

2023 **Keynote speech, international meeting:** International Guidelines in Traditional Medicine Research: Opportunities & Challenges in Real-World Studies. Bo'ao Summit on Real-World Studies. Bo'ao, Hainan, China, 31st Oct. 2023.

Keynote speech, international meeting: Harmony without being uniform: International Guidelines & Standards in R&D of Traditional Medicine. Chinese Medicine and Human Health Conference, London, UK, 7-8th Oct. 2023.

Invited talk, international meeting: Proteomics enables a systems view on TGF-β1-induced fibrogenesis and the pharmacology & toxicology of herbal antifibrotics. The 11th Annual Meeting of the GP-TCM Research Association, Leiden, The Netherlands, 18th Sept. 2023.

Invited talk, international meeting: International Good Practice Guidelines & Standards Pertinent to Traditional Medicine Research. 2023 China APEC Cooperation Fund International Symposium. Regulatory Science & International Sharing of TM S&T Innovation. Beijing, China, 5th July 2023.

Invited talk: Let there be light: Let TCM wisdom inspire modern nephrology & pharmacology. Institute of Integrated Chinese & Western Medicine, Shanghai University of Traditional Chinese Medicine, 13th April 2023.

Invited talk, international meeting: Proteomics enables a systems view on fibrogenesis and reveals novel mechanisms of herbal antifibrotics. The 1st International Network Pharmacology Conference and the 2023 Summit of the Network Pharmacology Specialty Committee, World Federation of Chinese Medicine Societies, Huangshan, Hubei, China, 1st April.

Invited lecture to undergraduate students: The importance of herbal medicine in a globalised world: Chinese herbal medicine as an example. School of Chinese Pharmacy, Beijing University of Chinese Medicine. 30th March

Invited lecture to undergraduate students: Chinese herbal medicine: A herbal journey with a nephrologist. School of Chinese Pharmacy, Beijing University of Chinese Medicine. 30th March

Invited talk to faculty members: International Good Practice Guidelines and Standards in Research & Development of Herbal Medicine. School of Chinese Pharmacy, Beijing University of Chinese Medicine. 29th March

2022 **Invited talk:** Proteomics enables a systems view on fibrogenesis and reveals novel mechanisms of herbal antifibrotics. The 6th Conference of the Geo-authentic Herb Multi-dimensional Evaluation Specialty Committee, World Federation of Chinese Medicine Societies, Chengdu University of Traditional Chinese Medicine, Chengdu, China, 11th January.

2021 **Invited talk:** Taming the Fire of Nephrotoxic Botanicals. The Specialty Committee of Research on Safety of Clinical Use of Drugs, World Federation of Chinese Medicine Societies, Shenzhen, China, 7th August 2021.

2019 **Invited talk:** Defining a principal renal defender: Collecting ducts and its retinoic acid signalling. School of Pharmacy, Sichuan University, Chengdu, Sichuan Province, China, 23rd October 2019.

Invited talk: Three decades of studies in the East & the West: Stay hungry, stay young. Xinxiang Medical University, Xinxiang, Henan, China, 18th October 2019.

Invited talk: Traditional Chinese Medicine for the Prevention and Treatment of Acute Kidney Injury: State of the Art and Frontiers. Panel 6, TCM for Critical Diseases. The 6th International Conference on the Modernisation of Traditional Chinese Medicine, Chengdu, China, 21-22 October.

Invited talk: Integrative Chinese Medicine Research of Weakening Kidney and Kidney-tonic Therapies. School of Chinese Medicine, Hong Kong Baptist University, 26th September 2019.

Invited talk: How TCM could inspire ground-breaking discoveries in modern medicine: A nephrologist point of view. Seminar on Research and Development of Chinese Medicines 2019, Committee on Research and Development of Chinese Medicine, Innovation and Technology Commission, Central Government Offices, Hong Kong, China, 24th September.

Invited talk: The Defensive Role for the Collecting Duct and Its Role in AKI and CKD. World Association of Chinese Renal Physicians, Qingdao, Shandong, China, 22nd September 2019.

Invited talk: Taming the Fire of Nephrotoxic Botanicals. Pharmacology & Toxicology session, the 7th Annual Meeting of the GP-TCM Research Association, Daegu, South Korea, 9th July 2019

Invited lecture: Integrating wisdom from West and East, to identify key blind spots and frontiers in modern nephrology research. Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China, 4th July 2019.

Invited talk: Let there be light: Let TCM wisdom inspire modern nephrology. World Summit of Chinese Medicine, Shenzhen, 29th June-1st July 2019.

Invited special session organiser and leading speaker: The collecting duct: A critical protector against renal tubulointerstitial injury? UK Kidney Week 2019, Brighton, 3-5 June 2019

Invited lecture: Let there be light: Let TCM wisdom inspire modern nephrology. Institute of Clinical Research, Japan-China Friendship Hospital, Beijing, 18th April 2019.

Invited lecture: Let there be light: Let TCM wisdom inspire modern nephrology. Department of Nephrology, Japan-China Friendship Hospital, Beijing, 18th April 2019.

Invited lecture: Focusing on A Major Blindspot in Modern Nephrology and Strive for a New Era in the Prevention and Treatment of AKI and CKD. School of Chinese Medicine, Beijing University of Chinese Medicine. 2nd April 2019.

Workshop with undergraduates: Let's Flourish at Each Stage of Our Lives. School of Pharmacy, Beijing University of Chinese Medicine. 1st April 2019.

Invited lecture: Traditional Chinese Medicine for the Prevention and Treatment of Acute Kidney Injury: Where are we? We are we going? School of Pharmacy, Beijing University of Chinese Medicine. 1st April 2019.

2018 **Keynote speech:** Traditional Chinese Medicine for Acute Kidney Injury. The 19th International Congress of Oriental Medicine, International Convention Centre of National Taiwan University Hospital, Taipei, Taiwan, 24th-26th November 2018.

Invited speaker: Efficacy- and omics-based research of anti-fibrotic Chinese herbal medicines. International Forum on Chinese Medicine Hong Kong Summit, Hong Kong International Convention & Exhibition Centre, Hong Kong, China, 5th August 2018.

Xu Q. Defining a principal renal defender: Collecting ducts and its retinoic acid signalling. School of Medicine, Aberdeen University, Scotland, UK, 17 August 2018.

Xu Q. Proteomics of Fibrosis and Antifibrotics. Henan University of Science & Technology, Luoyang, Henan, China. 29th March 2018.

Xu Q. The Making of Steel: MBBS education and training of medical professionals in the UK. Luohe Medical School, Henan, China. 22nd March 2018.

Xu Q. AKI & CKD: The Blind Spots and Research Directions. A Lecture for Members of Faculty and MBBS students. Luohe Medical School, Henan, China. 22nd March 2018.

Xu Q. Brilliance Comes from Every Stage of Life: A Lecture for MBBS students. Luohe Medical School, Henan, China. 22nd March 2018.

Xu Q. Proteomics of Fibrosis and Antifibrotics. School of Pharmacy, Beijing University of Chinese Medicine. 21st March 2018.

2017 **Keynote speech: Xu Q**. Efficacy- and proteomics-based research of anti-fibrotic Chinese herbal medicines. Association of Tradition Chinese Medicine & Acupuncture UK, London, 29 October 2017.

Xu Q. How to deal with nephrotoxicity in TCM? The 16th Annual Meeting of the Consortium for Globalization of Chinese Medicine. Guangzhou, August 2017.

Xu Q. An Annual Report of the UKCGCM. The 16th Annual Meeting of the Consortium for Globalization of Chinese Medicine. Guangzhou, August 2017.

Xu Q. A Secretomic Study of TGF-beta-induced Fibrogenesis and the Anti-fibrotic Effects of Scutelariae Radix and Baicalein. The 16th Annual Meeting of the Consortium for Globalization of Chinese Medicine. Guangzhou, August 2017.

Keynote speech: Xu Q. The quest for modernisation of traditional Chinese medicine: A global view on quality and standardisation. The International Conference on Quality and Efficacy of Chinese Medicine, Shiyan, Hubei, August 2017 (invited international plenary)

Xu Q. Retinoic acid signalling: Central regulator of renal defences? An invited talk at Xiangyang Hospital, Hubei, August 2017.

Xu Q. King's CICM and the hunt for antifibrotics. An invited talk at Hubei University of TCM, Hubei, August 2017.

2016 **Keynote speech: Xu Q.** Chinese materia medica: A reflection on what we have learnt from the EU's FP7 GP-TCM Project. Panel 3, The 5th International Conference on the Modernisation of Traditional Chinese Medicine, Chengdu, China, 24-25 October.

Keynote speech: Xu Q. Use science to explore tradition; use tradition to tackle fibrosis. Panel 8, The 5th International Conference on the Modernisation of Traditional Chinese Medicine, Chengdu, China, 24-25 October.

2015 **Xu Q**. The quest for modernisation of traditional Chinese medicine: A global view from Europe. KCL Pharmacology Society, King's College London, 2nd November.

Keynote speech: Xu Q. The quest for modernisation of traditional Chinese medicine: Focus on good practices and quality. The Launch Conference of the Geo-authentic Herb Multi-dimensional Evaluation Specialty Committee, World Federation of Chinese Medicine Societies, Chengdu University of Traditional Chinese Medicine, Chengdu, China, 25th October

Keynote speech: Xu Q. Herbal Medicines for Acute Kidney Injury: Evidence, Gaps and Frontiers. The 12th Consortium for Globalisation of Chinese Medicine Annual Meeting, London, Ontario, Canada, August 2015.

Xu Q. The quest for modernisation of traditional Chinese medicine: A global view from Europe. School of Pharmacy, China Medical University, Taichung, Taiwan, 10th April.

Xu Q. King's Centre for Integrative Chinese Medicine & its research on anti- and pro-fibrotic botanicals. National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Institute of Traditional Medicine, National Yang-Ming University, Taiwan, 8th April.

Xu Q. *Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era* under European Union's Seventh Framework Programme. National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Institute of Traditional Medicine, National Yang-Ming University, Taiwan, 8th April.

Xu Q. Retinoic acid signalling: A master regulator of renal defences. School of Pharmacy, Beijing University of Chinese Medicine. 27th March.

2014 **Xu Q.** TCM knowledge-based discovery of antifibrotics. The 3rd Annual Meeting of GP-TCM RA, Nanjing, China, 18th July.

Xu Q. Hunting for antifibrotics. PuraPharm, Nanning, China, 16th July.

Xu Q. Vitamin A, the Kidney and Kidney Diseases. Chengdu University of TCM Affiliated Hospital, Chengdu, China, 15th July.

Xu Q. Hunting for antifibrotics. Chengdu University of TCM, Chengdu, China, 14th July.

Xu Q. What have we learnt from GP-TCM, the EU's 1st EU-China Collaboration under its Seventh Framework Programme? The Southwest Daodi Chinese Medica Innovation 2011 Project, Chengdu, China, 13th July.

Xu Q. *King's Centre for Integrative Chinese Medicine and Our Research on Anti- and Pro-fibrotic Herbs*. Beijing University of Traditional Chinese Medicine, 2nd April.

Xu Q. *On TCM – Some Updates from Europe*. Beijing University of Traditional Chinese Medicine, 2nd April.

2013 **Xu Q**. Panellist talk entitled *King's Centre for Integrative Chinese Medicine*. Interregional Collaborations in Industry and Academia Session, Consortium for Globalization of Chinese Medicine Meeting, Graz, Austria, 27th August.

Xu Q. Why am I here? The Herbal Journey of a Nephrologist. International symposium on medicinal plants and quality control, Brussels, Belgium, on the 23rd-24th May.

2012 **Xu Q.** What have we learnt from the EU's first Coordination Action on TCM Research? Shanghai International Traditional Chinese Medicine Conference and the 1st GP-TCM Research Association Annual Meeting, 20th-21st October, Shanghai, China.

Xu Q. From anti-fibrotic Chinese herbs to GP-TCM, the first EU-China collaboration on modernisation of Traditional Chinese Medicine (TCM). Chengdu University of TCM, 16th October, Chengdu, China.

Xu Q. From anti-fibrotic Chinese herbs to EU's first Coordination Action on TCM Research. China-Japan Friendship Hospital, 27th August, Beijing, China.

Xu Q. From anti-fibrotic Chinese herbs to GP-TCM, the first EU-China collaboration on modernisation of Traditional Chinese Medicine (TCM). National Engineering Research Centre for Modernisation of TCM, 24th August, Zhuhai, China.

Xu Q. Discovery and rediscovery of anti-fibrotic Chinese herbal medicines. CGCM Annual Conference, 22nd August, Macao, China.

Xu Q. Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era. CGCM Annual Conference, 21st August, Macao, China.

Xu Q. From anti-fibrotic herbs to GP-TCM. Northwest University. 15th August, Xi'an, China.

Xu Q. Retinoic acid and the kidney: Focus on target genes, The Vitamins Workshop, 11th June, Guy's Hospital, London, UK.

Xu Q. Target genes of endogenous retinoic acid and retinoic acid receptors in collecting duct cells: a pan-genomic view. Southwest and East Kidney Society (SWEKS) Annual Meeting, 25th April, Warren House, Kingston-Upon-Thames, UK.

Xu Q. Concluding remarks: Integrity, Integration and Innovation. The GP-TCM Congress, 15th -18th April, Leiden, the Netherlands.

Xu Q. An introduction to The FP7 GP-TCM Project. Set the Scene: Roadmap to Evidence-Based TCM. The GP-TCM Congress, 15th -18th April, Leiden, the Netherlands.

Xu Q. The GP-TCM Research Association. The GP-TCM Final Conference. 12th-13th April, Rolduc, Kerkrade, the Netherlands.

Xu Q. Key renal target genes of retinoid system. 30th March, Comprehensive Biomedical Research Centre, King's College London, UK.

2011 **Xu Q**. Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era. The Association of Traditional Chinese Medicine (UK) Annual Meeting, Middlesex University, Hendon, London, November 2011.

Xu Q. Discovery and rediscovery of anti-fibrotic and pro-fibrotic activities from Chinese materia medica. The 2011 Shanghai International Conference on TCM and

Natural Medicine. October 2011. The talk was invited by the organizing committee and kindly sponsored by the British Consulate General based in Shanghai, China, with funding provided by The Department for Business, Innovation and Skills (BIS), United Kingdom.

Xu Q. *In vitro* models of fibrosis suitable for high-throughput screening and discovery of anti-fibrotic and pro-fibrotic herbal entities. Department of Biomedical Science, The School of Life Sciences, University of Westminster, London, UK, October 2011.

Uzuner H, **Xu Q.** Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era. The 8th World Congress of Chinese Medicine, Westminster Central Hall, London, September 2011.

Xu Q. TCM knowledge-based discovery and rediscovery of *in vitro* anti-fibrotic and pro-fibrotic activities from Chinese materia medica. The 8th World Congress of Chinese Medicine, Westminster Central Hall, London, September 2011 (Plenary speech)

Xu Q. Knowledge-based discovery and re-discovery of *in vitro* anti-fibrotic and pro-fibrotic activities from Chinese materia medica. The 8th Congress of Consortium for Globalisation of Chinese Medicine. Shanghai, August 2011. (Panellist speech)

Xu Q. What does TCM industry needs and what academia can offer? The 8th Congress of Consortium for Globalisation of Chinese Medicine. Shanghai, August 2011. (Panellist speech)

Xu Q. Training EU scientist towards good practice in complex herbal product research: A FP7 Marie Curie grant revision discussion. The 2nd Annual Meeting of the GP-TCM Consortium. University of Minho, Braga, Portugal, July 2011.

Xu Q. "The New Society". The 2nd Annual Meeting of the GP-TCM Consortium. University of Minho, Braga, Portugal, July 2011.

Xu Q. Biological activity and target genes for endogenous retinoic acid in mouse kidney cells. MRC Centre for Transplantation. KCL, London, UK, July 2011.

Xu Q. Target genes for endogenous retinoic acid in mouse collecting duct cells. 15th European Nephrogenesis Workshop. Institute of Child Health, UCL, London, UK, May 2011.

Xu Q. *In vitro* models of fibrosis, anti-fibrotic herbs and the GP-TCM and TEST-GP Consortia on modernisation of Chinese medicine. Hainan Medical College, China (April 2011); Xinxiang Medical University, China (May 2011).

Xu Q. TGF-beta and retinoids: Crosstalk in development, immunity and tissue repair. The Frisk Seminar Room Presentation Series. King's College London, March 2011.

Xu Q. A tale of a KRUK-sponsored research project on anti-fibrotic herbs. Kidney Research UK fundraising event at Leeds Castle, UK, March 2011.

Xu Q. The roles for activated vitamin A in kidneys before and after birth. James Black Centre Seminar Series, King's College London, Feb. 2011.

2010 **Xu Q**. Training EU scientists towards good practice in TCM research: A FP7 Marie Curie grants revision discussion. The 1st Annual Meeting of the GP-TCM Consortium. Henley Business School, Henley-Upon-Thames, UK, July 2010.

Xu Q. A new TCM research society of Europe. The 1st Annual Meeting of the GP-TCM Consortium. Henley Business School, Henley-Upon-Thames, UK, July 2010.

Xu Q. From anti-fibrotic herbs to GP-TCM, a FP7 consortium on Chinese medicine research. University of Hong Kong (HKU). The trip was kindly sponsored by the KCL-HKU partnership fund.

Xu Q. From anti-fibrotic herbs to GP-TCM, a FP7 consortium on Chinese medicine research. University of Macau (UM). The trip was kindly sponsored by the KCL-HKU partnership fund and UM.

2009 Wong YF, Kopp JB, Roberts C, Maden M, Scambler PJ, Rankin AC, Dutt N, Noor M, Hendry BM, **Xu Q**. Physiological retinoic acid activity in the collecting ducts of

postnatal mouse kidneys. American Society of Nephrology Annual Meeting and Renal Week. San Diego, CA, October 2009 (presented by WYF)

Xu Q. Good Practice of Chinese Medicine Research in the Post-genomic Era. The 8th CGCM Conference, Nottingham, August 2009.

Hu Q, **Xu Q**. From anti-fibrotic herbs to GP-TCM, a FP7 consortium on Chinese medicine research. The James Black Centre Seminar Series. KCL, London, UK, Feb. 2009. (Presented by HQ and XQ)

Hu Q, Hendry BM, **Xu Q**. Discovery of herbal medicines with *in vitro* anti-fibrotic activities. Keystone Symposia: Fibrosis. Keystone, Colorado, Jan. 2009 (Presented by XQ).

Xu Q. From anti-fibrotic herbs to GP-TCM, a FP7 consortium on Chinese medicine research. The General Hospital of Chinese PLA, Beijing, Jan. 2009.

Xu Q. GP-TCM: Its Mission, Strength and Weakness. The Sino-EU GP-TCM Workshop, Beijing.

2008 **Xu Q.** From anti-fibrotic herbs to GP-TCM, a FP7 Consortium on Chinese medicine research. The Annual Meeting of the Chinese Life Scientists Society in the UK. Oxford, UK.

Xu Q. Discovery of herbs with *in vitro* anti-scarring activities. Traditional Chinese Medicine Week UK, Royal Society of Medicine, London, UK

2007 **Xu Q**. Searching for Antifibrotics from herbs. The Annual General Meeting of The Association of Traditional Chinese Medicine (UK), University of Westminster, London.

Xu Q. Searching for Antifibrotics. Sir James Black Centre, KCL.

Xu Q. *In vitro* models of fibrosis for screening anti-fibrotic activities. 13th Meeting of the Chinese Life Scientists Society in the UK, Cambridge, UK.

Xu Q. High-throughput screening of anti-fibrotic drugs. Teleconference with the FibroGen.

Xu Q. Antifibrotic activities of herbal medicines: To be revisited using *in vitro* models of fibrosis. Meeting with Phynova senior scientists at KCL, June.

Xu Q. Searching for antifibrotics. Renovo, Manchester, UK, June.

Xu Q. *In vitro* models of TGF-beta-induced fibrosis suitable for high-throughput screening of anti-fibrotic agents. Keystone Symposia. Molecular Mechanisms of Fibrosis: From Bench to Bedside. Tahoe City, CA, March 2007.

2006 **Xu Q.** *In vitro* models of fibrosis suitable for high-throughput screening of anti-fibrotic drugs. Teleconference with the Novartis Horsham Research Centre

Xu Q. Searching for antifibrotics: *In vitro* models of fibrosis suitable for high-throughput screening of anti-fibrotic drugs. Xinxiang Medical University, Henan, China; Zheng Zhou University (ZZU), Henan, China; Peking University First Hospital, Beijing, China; Beijing University of Chinese Medicine, Beijing, China.

Xu Q. *In vitro* models of fibrosis suitable for high-throughput screening of anti-fibrotic drugs. Annual Meeting of the Chinese Society of Nephrology, Xiamen, China.

Xu Q. Retinoid system in health and diseases of the kidney. Institute of Child Health, UCL, London.

Xu Q. *In vitro* models of fibrosis for anti-fibrotic drug development. St Helier's Southwest Thames Renal & Transplantation Unit, London.

2005 **Xu Q.** TGF-β, CTGF and Fibrosis. Kidney Disease Section, NIDDK, NIH, Bethesda, Maryland, USA.

Xu Q. Retinoids, Immunity and Systemic Lupus Erythematosus. Kidney Disease Section, NIDDK, NIH, Bethesda, MD, USA.

Xu Q. The Retinoid system: Central protective machinery against tissue injury? Kidney Disease Section, NIDDK, NIH, Bethesda, MD, USA.

Xu Q. Retinoids in Nephrology: Promises and pitfalls. PLA Postgraduate School of Medicine, Beijing, China.

Xu Q. Towards understanding the anti-NFκB activity of retinoid: Establishing a biosensor system in rat mesangial cells. PLA Postgraduate School of Medicine, Beijing, China.

Xu Q. Retinoid treatment of nephritides: Encouraging experimental data and challenging hypotheses. The 1st Affiliated Hospital, Xinxiang Medical College, Henan, China.

2003 **Xu Q.** Retinoids in nephrology: Promises and potential limitations. The 10th Annual Meeting of the Chinese Life Scientists Society in the UK, Oxford.

2001 **Xu Q.** Transcriptional induction of MKP-1 by retinoids: Involvement of different nuclear receptors and role in the anti-apoptotic effect of retinoic acid. The 9th Annual Meeting of the Chinese Life Scientists Society in the UK, London.

INVITED CHAIR/MODERATOR/PANELLIST

2025 Review panel member of the abstracts for the Young Scholars Award, The Fifth International Forum of *Integrative Medicine in Nephrology and Andrology, Nanjing*, China, July 2025

Panellist for "TCM in Europe - opportunities and challenges" / GA - Society for Medicinal Plant and Natural Product Research, 24th Jan. 2025, online.

2024 Panellist for Discussions. Chinese Medicine and Human Health Conference, Challenges & Opportunities in Chinese Medicine: Traditional and Modern Perspectives, 19th October 2024, London, UK.

Review panel member of the abstracts for the Young Scholars Award, The Fourth IMNA International Forum on October 26, 2024.

Co-Chair of abstract marking and travel award selection panel, Co-Chair the Pharmacology & Toxicology Interest Group Session, and moderator of 2-min flash poster presentations. The 12th Annual Meeting of the GP-TCM Research Association, Macao, China, Aug. 2024.

2023 Co-Chair of abstract marking and travel award selection panel and the Pharmacology & Toxicology Interest Group Session: The 11th Annual Meeting of the GP-TCM Research Association, Leiden, The Netherlands, 18th Sept. 2023.

2021 Session Co-Chair, The 9th Good Practice in Traditional Chinese Medicine Research Association Annual Meeting (virtual). COVID 19 – the global role of herbal medicines. 9th & 10th November 2021.

2020 Invited opening session guest chair: Annual Meeting of UK Federation of Chinese Medicine Practitioners (virtual). 25th December 2020.

2018 Session Panellist, Bioinformatics: “Omics” Approach and Data Analysis, The 17th Annual Meeting of the Consortium for Globalization of Chinese Medicine. Borneo Convention Centre Kuching (BCCK), Malaysia, August 10, 2018 (Friday)

2018 Chairman of a Plenary Session by Professor Zhongzhen Zhao, The 6th GP-TCM Research Association Meeting, Royal Botanic Garden Kew and London South Bank University, 5th July 2018

2018 Panellist. Discussion Forum on "Medicines from Plants (MfP) and TCM" and the Opening Ceremony to establish a base for long-term international collaboration, Hui Xian City, Henan, China. 3rd April 2018.

2016 Deputy-Chair, Panel 8, the 5th International Conference on the Modernization of Traditional Chinese Medicine, Chengdu, China, October 23-25, 2016. The meeting is co-sponsored by the Ministry of Science and Technology, Ministry of Public Health, China Food and Drug Administration, State Administration of Traditional Chinese Medicine, and People’s Government of Sichuan Province.

Session Chairman, The 22nd Chinese Life Scientists Society in the UK Annual Conference, Sept 8, 2016, Imperial College London, London, UK

2015 Session Co-Chair, The Launch Conference of the Geo-authentic Herb Multi-dimensional Evaluation Specialty Committee, World Federation of Chinese Medicine

Societies, Chengdu University of Traditional Chinese Medicine, Chengdu, China, 25th October.

Session Chairman, the Polychemical Activities and Mechanism Study III (Metabolism, Drug Interaction and Toxicity) Session, the 14th Consortium for Globalization of Chinese Medicine Annual Meeting, 17-20th August, London, ON, Canada.

Plenary & Keynote Session Chairman, the 4th Annual Conference of the Good Practice in Traditional Chinese Medicine Research Association, 15th July, Mons, Belgium.

Organiser & Chair, Renal Sciences Research Meetings (First round), KCL.

2014 Moderator, Clinical Studies and Systems Biology, The 3rd Annual Conference of the Good Practice in Traditional Chinese Medicine Research Association, 18th July, Nanjing, China.

2013 Chairman, Plenary Session 1, the 2nd Annual Conference of the Good Practice in Traditional Chinese Medicine Research Association, 30th August, Graz, Austria.

Panellist, the Interregional Collaborations in Industry and Academia Session, Consortium for Globalization of Chinese Medicine Meeting, Graz, Austria, 27th August.

Poster session moderator, DIIID/DTIMB PhD Student Research Showcase Day. 27th June, Strand Campus, KCL, London. UK

2012 Session Chair, the 18th Annual Meeting of the Chinese Life Scientists Society in the UK. 7-8th September, London, UK.

Panellist, Polychemical Activities and Mechanism Study II: Metabolic, Neural Diseases, Aging Process and Others. Consortium for Globalization of Chinese Medicine Annual Meeting, 22nd August, Macao, China.

Session Chair, Dialogue on Human Health between Traditional Chinese Medicine Culture and Western Medicine, 10th-11th May, Bologna, Italy.

Chair, Opening Plenary. The GP-TCM Congress, 15th -18th April, Leiden, the Netherlands.

Chair, *In Vivo* Pharmacology. The GP-TCM Final Conference. 12th-13th April, Rolduc, Kerkrade, the Netherlands.

Chair, Opening Plenary. The GP-TCM Final Conference. 12th-13th April, Rolduc, Kerkrade, the Netherlands.

2011 Panellist, Interregional Collaborations in Industry and Academia Session, The 10th Consortium for Globalization of Chinese Medicine Meeting, Shanghai, China (August).

Panellist, Herbal Resources III (Natural Products and Biological Activities), The 10th Consortium for Globalization of Chinese Medicine Meeting, Shanghai, China (August).

Chair, “The New Society”, The 2nd Annual Meeting of the FP7 GP-TCM Consortium, Braga, Portugal (July).

Chair, “TEST-GP”, The 2nd Annual Meeting of the FP7 GP-TCM Consortium, Braga, Portugal (July).

Panellist, Quest for Personal Health: Exploring the Emergent Interface of East Asian Medicines and Modern System Sciences, an international conference Jointly organized by Jan van der Greef (TNO, The Netherlands), Bridie Andrews (Bentley University, USA) and Volker Scheid. The International Association for the Study of Traditional Asian Medicines (IASTAM, UK), University of Westminster (UK), London (June).

2010 Chairman of the meeting and host of 2 sessions. The 1st GP-TCM Annual Meeting, Henley Business School, Henley-on-Thames, UK (July).

2007 Session Co-Chair, The 15th Annual Meeting of the Chinese Life Scientists Society in the UK. London (September).

Panellist, The Consortium for Globalisation of Chinese Medicine Meeting, Nottingham, UK (August).

One of the main organisers, The Sino-EU GP-TCM Workshop, Beijing (January).

2008 Session Chairman, The 14th Annual Meeting of the Chinese Life Scientists Society in the UK. Oxford.

2007 Session Chairman, The 13th Meeting of the Chinese Life Scientists Society in the UK, Cambridge, UK.

2003 Session Chairman, The 10th Annual Meeting of the Chinese Life Scientists Society in the UK, Oxford, UK.

1998 Organiser, a national training course for the diagnosis and management of chronic renal failure. General Hospital of the Chinese PLA, Beijing, China.

ADMINISTRATION & ENABLING ACTIVITIES

2025 **Proposer and co-organiser** of a UK Kidney Week 2025 session: "Glomerular Parietal Epithelial Cells: An Exciting Frontier in Renal Cell Biology".

2024 Marking the 1st anniversary of the publication of the 2023 Academy of Medical Sciences report calling for changes to employment and funding to safeguard the future of health research in the UK, e-mailed the Senior Management of KCL (above Head of School) to urge the university to conduct an internal check to discover structural and cultural problems and to propose mitigating and rescuing strategies. My e-mail was as follows.

"10th May is the 1st anniversary of the publication of the 2023 Academy of Medical Sciences report calling for drastic changes to safeguard the future of health research in the UK. Many identified problems were long-standing, cultural and structural.

To mark this occasion, I attach a one-pager commentary on the 2023 AMS report for your perusal. It might be a good time to ponder what has happened since the publication of the AMS report and what we should do next to mitigate common and unique problems we face at King's.

Recently, our School completed the 2024 Work Culture Survey, which was a follow-up one from 2022. The attached paper and the 2023 AMS report may provide a useful backdrop for us to devise our mitigating strategies and forward plans."

- The shared *Lancet* World Report: "Burki T. Warnings over the future of UK medical research. *Lancet* 2023;401:1641"—Four key areas of concern were identified by the AMS report: research culture itself and its precarious nature and poor diversity, the lack of mobility between sectors, the inadequate funding model, and the obstacles to embedding research within the NHS. These issues are mostly long-standing and structural and are further exacerbated by Brexit, the COVID-19 pandemic, and the UK's ongoing economic troubles. "Research is not a luxury". However, when all the existing issues, research becomes one. To address the existing issues, the concept of "collective responsibility" is proposed.

2024 On 17th April, brought the latest GDB Mortality Report published by *The Lancet*, the latest *Nature Review Nephrology* International Consensus article and editorial, as well as *Nature* editorial on the global kidney disease crisis to the attention of the President, Senior VP (Health), Dean and Vice-Dean (Health) of the Faculty (FoLSM), Heads of the School (SIMS), the Department (DIB) and the Centre (CNUT) and called for adjusting our strategy to revive Nephrology at King's:

- GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024 Apr 3: PMID: 38582094
- Editorial. Time to sound the alarm about the hidden epidemic of kidney disease. *Nature* 2024;628:7-8.
- Editorial. Kidney disease: a global health priority. *Nat Rev Nephrol* 2024. https://doi.org/10.1038/s41581-024-00829-x

- Francis A *et al.* Chronic kidney disease and the global public health agenda: an international consensus. *Nat Rev Nephrol* 2024. https://doi.org/10.1038/s41581-024-00820-6

2024 7th Feb., met Head of DIB, proposing to establish two research themes, *King's Inflammation Research* (KIR) and *King's Fibrosis Research* (KFR) under the umbrella of DIB, and to establish a DIB Denmark Hill Forum to foster campus-focused exchanges both within and beyond DIB, including promoting and enhancing external exchanges and hosting DIB/SIMS activities.

2023 Scientific Committee, abstract and poster marker, The 11th Annual Meeting of the GP-TCM Research Association, Leiden, The Netherlands, 18th Sept. 2023.

2022 Organising Committee, the 10th GP-TCM Research Association Annual Meeting in celebration of the 10th Anniversary of the Association (virtual)

2022 **Session proposer and organiser**, "What should renal patients and care providers know about herbal products, as well as herbal- and nutrient-drug interactions?", UK Kidney Week 2022

2022 Abstract reviewing panel, UK Kidney Week 2022

2019 **Session proposer and organiser** "Mechanisms of Tubulointerstitial Injury", UK Kidney Week 2019

2019 Abstract reviewing panel, UK Kidney Week 2019

2019 In early September, I e-mailed Principal Ed Byrne with a series of suggestions on the Institute of Pharmaceutical Science, PDR, staff wellbeing and continuous learning, importance of Small Groups, integrative Chinese medicine and King's China initiatives. Ed replied: "You make a lot of positive comments in your letter which I'm delighted to read." With my consent, Ed has cascaded the suggestions to related Vice Presidents and Executive Deans.

2019-2022 Elected Member of the Board of Directors, GP-TCM Research Association.

2018 Scientific and local committee member, The 6th GP-TCM Research Association Meeting, Royal Botanic Garden Kew and London South Bank University, 3-6 July 2018

2017-2023 Standing Committee Member, 1st and 2nd Board of Specialty Committee of Research on Safety of Clinical Usage of Drugs of the World Federation of Chinese Medicine Societies.

2017 International Advisory Committee, The 10th Pong Ding Yuen International Symposium on Traditional Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong.

2017- Board Member & Newsletter Editor-in-chief, The GP-TCM Research Association http://www.gp-tcm.org

2017- Trustee, International Society for Chinese Medicine, Macau, China http://www.iscm.org.mo/en/index2.php

2016 Senior Scientific Committee Member, The 22nd Chinese Life Scientists Society in the UK Annual Conference, Sept 8, 2016, Imperial College London, London, UK

2016 Commented on draft "Changing King's for a Changing world: A strategic vision to 2029": (i) The document is very good indeed, but it somehow lacks a sentence that governs the whole document, which is an updated motto. As it stands (not included in the document), the King's motto is 'Sancte et Sapienter' (Holiness and Wisdom). Is this till suitable for a changing world? Isn't it a good opportunity to review the motto of King's and all the institutions merged with King's in the past years to postulate a new motto, which can inspire the whole King's community and can govern this new strategic vision document? (ii) King's is a Health-heavy institution. We should not only emphasise education and research on health, but also emphasise the wellbeing of staff and students – healthier is happier and more productive! (iii) It is certainly an excellent idea to not only bring about a strategic vision document, but more

importantly to plan concrete projects to materialize the vision. I offer the "King's Centre for Integrative Chinese Medicine" initiative as one of the ten projects and initiatives to be showcased in the strategy.

2016 Led the development of an 8-page updated business plan of the King's Centre for Integrative Chinese Medicine and submitted it to the Senior Management of King's and KHP. "I like the fact that the paper also suggests a clear focus going forward… You outline what you can achieve," commented Dr. Joanna Newman, King's Vice-Principal International. "I think the topic is very open to a truly interdisciplinary approach and it would be a missed opportunity if that was not realized," added Prof. Jonathan Grant, King's Assistant Principal, Strategy.

2016 Organising Committee Member of the 4th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products, August 29-31, 2016, Sao Paulo, Brazil.

2016 Scientific committee member of the 5th Annual Meeting of GP-TCM Research Association-cum-Summit on Compendium of Materia Medica *and Innovative Drug Discovery in Chinese Medicine.* August 9-10, 2016, Hong Kong, China.

2015-2019 Vice Chairman, Geo-authentic Herb Multi-dimensional Evaluation Specialty Committee, World Federation of Chinese Medicine Societies.

2015- Member of the MSc Pharmacology and Drug Discovery Skills Assessment Sub-Board, King's College London, chaired by Dr. Sarah Salvage.

2015- Expert Member, Standard Approval Committee, The International Index for Chinese Medicine Systems, the World Federation of Chinese Medicine Societies.

2014-2018 Consultant Member, the 1st Board of the Post-Marketing Surveillance Committee, the World Federation of Chinese Medicine Societies.

2014-2018 Executive Council Member, the 1st Board of the Professional TCM Qi-Blood Committee, the World Federation of Chinese Medicine Societies.

2014-2018 Executive Council Member, the 2nd Board of the Specialty Committee of TCM Pharmaceutical Analysis, the World Federation of Chinese Medicine Societies.

2014-2015 Scientific committee member of the 4th Annual Conference of the Good Practice in Traditional Chinese Medicine Research Association, 13th-15th July, Mons, Belgium.

2014 Scientific committee member of the 2014 Shanghai International Conference on Traditional Chinese Medicine and Natural Medicine, 16th-17th October, Shanghai, China.

2014 Scientific committee member of the 3rd Annual Conference of the Good Practice in Traditional Chinese Medicine Research Association, 18th-20th July, Nanjing, China.

2013 Scientific committee member of the 2nd Annual Conference of the Good Practice in Traditional Chinese Medicine Research Association, 30th August, Graz, Austria.

2012-2014 Vice President, Vice Secretary-General, Member of the Executive Council and Board of Directors, Convener of Board and Executive Council Meetings, Deputy Newsletter Editor-in-chief. The Good Practice in Traditional Chinese Medicine Research Association (The GP-TCM RA); including leading its registration as a UK charity:

2012 Meeting secretary in charge of minutes-taking and meeting report, International Symposium on the Standardization and Cooperation of Traditional Chinese Medicine, convened by State Administration of TCM, 23rd October, Beijing, China.

2012 Scientific committee member of the Shanghai International Traditional Chinese Medicine Conference, 20th-21st October, Shanghai, China.

2012 Scientific committee member and one of the core organisers, the GP-TCM Final Conference, 12th-13th April, Rolduc, Kerkrade, the Netherlands.

2012 Scientific committee member and one of the core organisers and fundraisers, the GP-TCM Congress, 15th -18th April, Leiden, the Netherlands.

2011 Co-Chair, the 2nd GP-TCM Symposium and Annual Meeting, University of Minho, Braga, Portugal, 21st-24th July 2010. The meeting gathers ~60 representative

consortium members to review the progress and pitfalls of the 2nd year and plans for the year to come.

2011- Biological Safety Officer, Department of Renal Medicine, Division of Transplant Immunology and Mucosal Biology, School of Medicine, KCL.

2011-2015 One of the two Elected Academic Board Member of the School of Medicine, King's College London. Chaired by the President and Principal of the university, the Academic Board is the body responsible for the academic work of the College in teaching, examining and research.

In addition to regular attendance and active participation of discussions, my own contributions are especially highlighted by the following: (i) my suggestion to emphasise not only staff but also students as sources of success of the university has been adopted in the values statement of King's; (ii) my proposals accepted for implementation now and in the future include to open research laboratories, to appoint personal tutors and expose students to TCM-featured SSCs and Electives so as to make medical and biomedical education more interesting, colourful and stimulating; (iii) my proposals to include discussions on "How can we support staff better to make them feel better and do better?" were commented as "very good ideas. I will follow up on this" by the President and Principal Prof. Ed Byrne in 2015; and this has contributed a series of investment and campaign in order to promote the wellbeing of Staff and Students, including the establish of King's Wellbeing as a central department in 2016, provision of more sports facilities and eventually a 17% increase of awareness of King's wellbeing provision in the 2017 King's Staff survey, the biggest leap in satisfaction rate (2017 vs 2015).

2010-2012 Secretary-General, the Organising Committee for *Good Practice in Traditional Chinese Medicine Research Association*, an association that has succeeded the FP7 *Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era* consortium since 1st November 2012.

2010 Chairman, the 1st GP-TCM Annual Meeting, Henley Business School, Henley-on-Thames, UK, 27th-30th July 2010. The meeting gathers ~50 representative consortium members to review the progress and pitfalls of the 1st year and plans for the 2nd year.

2009 Initiator and fundraiser of the Sino-EU GP-TCM Workshop, Beijing, 12-13 Jan. 2009. Attendees include senior officers from the European Commission and China, 25 top scientists from Europe and 80 from China. The theme of the meeting is EU-China collaborations in Chinese medicine research in the post-genomic era.

2007-2009 President, the Chinese Life Scientists Society in the UK (CLSS-UK). The Society was founded in 1992. It is a devoted link between Chinese life scientists in the UK and is the only British organisation that represents all the Chinese scientists in the broad field of life sciences. CLSS-UK has ~5000 members, including research students and scholars, academics, scientists, bioengineers, as well as clinicians.

2008-2009 Non-Fellow Executive Vice President, Chairman of the Fellowship Nomination Committee, the Academy of Life Sciences for Chinese in the UK (ALSC-UK). The virtual academy is the senior members' club of CLSS-UK. Elected fellows of the Academy are currently 31 elected senior scientists, equivalent to university professors, in academia, governmental and non-governmental institutions and pharmaceutical companies in the UK.

2007-2012 Programme Lead, Chairman of the Steering Committee and Chairman of the Coordination Office, the FP7 GP-TCM EU-China Consortium on Chinese Medicine Research. This collaborative network is funded by the Commission (~1 million Euro for 3.5 years) and is focused on good practice of traditional Chinese medicine research. The consortium comprises ~200 scientists from more than 100 institutions in 24 countries.

Member of 4 work packages of the GP-TCM Consortium: WP4 (*in vitro* pharmacology), WP5 (*in vivo* pharmacology), WP7 (industrial R&D and regulatory issues) and WP10 (management).

2007-2008 Editor, the FP7 GP-TCM Consortium Newsletters.

2003-2005 Group Leader, Centre for Nephrology, Royal Free and University College Medical School, University College London.

2003-2005 Secretary-General and then Vice President, Chinese Life Scientists Society in the UK.

EDITORSHIP AND EDITORIAL BOARD

2024-2027 Editorial Board, Digital Chinese Medicine

2024- Editorial Board, Journal of Integrative Medicine

2023- Topic Guest Associate Editor. Frontiers in Cell and Developmental Biology.

2022- Editorial Board, Science of Traditional Chinese Medicine

2021-2022 Topic Guest Associate Editor. Frontiers in Pharmacology - Ethnopharmacology.

2021-2022 Topic Guest Associate Editor. Frontiers in Cell and Developmental Biology.

2021 Editorial Board, Integrative Medicine in Andrology & Nephrology

2019- Editorial Board, Journal of Chengdu University of Traditional Chinese Medicine

2019- Deputy Editor-in-chief, World Journal of Traditional Chinese Medicine

2018-2020 Editorial Board, Experimental Biology and Medicine

2014- Editorial Board, Scientific Reports

2014- Editorial Board, World Journal of Traditional Chinese Medicine

2012- Editorial Board, Chinese Journal of Natural Medicines

2012- Editorial Board, Journal of Traditional and Complementary Medicine

PEER EXPERT EVALUATION ACTIVITIES

2020- Springer Nature

2016- Elsevier

2015- Health and Medical Research Fund, Hong Kong

2014- Science

The University of Macau

Horizon 2020 and Horizon Europe; expert registration No. EX2013D162096

2013- Deanship of Scientific Research, King Abdulaziz University, Saudi Arabia

The Association of Commonwealth Universities; The University of Malta

2012- Medical Research Council (MRC), UK

2011- Biotechnology and Biological Sciences Research Council (BBSRC), UK

Kidney Research UK and the British Renal Society Joint Fellowship, UK

2010- The French National Research Agency, France

PROFESSIONAL TRAINING

2026 PhD Supervisor Refresher training webinar, KCL

2024 3-day training on Analysis of Single-Cell RNA-seq Data (ONLINE), Bioinformatics Training Facility, University of Cambridge

2024 Human Tissue Act training course, King's College Hospital Trust

2024 Home Office Project Licence Holders Training, Royal Veterinary College

2023 Two-day training for biological safety supervisors, KCL

2020 PhD Supervisor Refresher training webinar, KCL

2018 Diversity Matters: Manager Training (24 July 2018, 1-4pm)

2018 BSU Refresher Training, Schedule 1 and IP Injection etc.

2016 Bullying and harassment awareness training, The Advisory, Conciliation and Arbitration Service.

2016 Admissions Tutor briefing, KCL.

2016 Breeding and a New Generation of Project Licences, KCL.

2016 Alternative Assessment, KCL.

2015 Mandatory Data Protection Training, KCL.

2015 Interview Training – all health programmes, KCL.
2014 PhD supervisor refresher training webinar, KCL.
2014 B-Mentor mentor induction workshop, UCL.
2014 Equal opportunity training certificate received, online.
2012 Two-day training for biological safety supervisors, KCL.
2012 Health & safety training for principal investigators. KCL.
2011 Laboratory health & safety training course, KCL.
2010 Project licence holder training course, Module 5, Imperial College London.
2009 PhD supervisor training course series, KCL.
2007 Human Tissue Act training course, King's College Hospital Trust.
2007 Being an appraiser training course, KCL.
2006 Writing for publications training courses, KCL.
2007 Writing effective research proposals training courses, KCL.
2006 Teaching training courses, KCL.
2005 NIH Grant Writing 102 Workshop, NIDDK, NIH, Bethesda, MD, USA.
2005 Online Animal Study Training Courses, NIDDK, NIH, Bethesda, MD, USA.
2001 Animals Act 1986 Training Courses, University College London (UCL), London, UK.
1999 Safety training courses on fire, radiation and gene modified organisms. UCL, London.
1997 Clinical nephrology training in Royal Melbourne Hospital for 2 weeks.

EXPERTISE

1. Ten years' experience in clinical practice as a clinical nephrologist;
2. Thirty years of research on renal science, molecular cell biology, and pharmacology;
3. International good practice guidelines and standards in research of integrative medicine, biomedicine and transgenic animal science.
4. Organisational, enabling, management and leadership skills developed through leading local, national, international collaborations.

STUDENT AND STAFF SUPERVISION

2024-2025 Supervised an MSci Pharmacology lab project. Establishing an In Vitro Model for studying the role of ALDH1A2-mediated retinoic acid synthesis in glomerular parietal epithelial cells (7BBM0019, Semester A (SM Cao).

Supervised a BSc Pharmacology dry lab project 6BBM0339. Mining single-cell RNA-seq databases to gain novel insights into mechanisms of chronic kidney disease and guide the development of novel therapies (Z Zhou).

Supervised 12 MBBS2 students' scholarly project module "Botanicals and the Health Care: Friends or Foes?"

2023-2024 Supervised an MSci Pharmacology dry lab project

- 7BBM0019 Semester A. Data mining and analysis of single-cell RNA-seq databases of healthy and diseased human and mouse kidneys and the mechanisms of action of renal therapies (O. Mitevska)

2023-2024 Supervised two BSc Pharmacology library projects (6BBM0319)

- Semester A. Targeting inosine-5'-monophosphate dehydrogenases (Impdh) as a therapeutic strategy: the state of the art" as my library project (Y. Malik)
- Semester B. Drug development targeting the ribosome pathway: opportunities and challenges (G. Monastyrskyj)

2022-2023 Provided four BSc Pharmacology projects, two for semester A and B, respectively.

2021-2022 Two BSc Pharmacology students A. Jaramillo Moyano (semester A) and S. Nahar (semester B).

2020 MSc Pharmacology Literature Dissertation (7BBMM006) and Experimental project Modules (7BBMM010). Student name: Farnaz Khadiviboroujeni

2019 Pharmacology library project (6BBM0319) entitled “Risk factors of kidney disease progression and therapeutic interventions”. Student name: Ryesha Higgs

2018- iBSc Pharmacology of a MBBS3 student Matthew Gallacher*.

Project title: Targeting the canonical vitamin A signalling to treat kidney disease:

* **Award-winning:** Awarded the British Society of Pharmacology iBSc research project prize.

2017-2019 A full-time postdoctoral research associate Dr Alexandros Papadimitriou.

Project title: MiR-acles in collecting ducts underlie albuminuria-induced renal fibrosis.

2016- BSc Pharmacology student Gulten Geneci.

Project title: Anti-fibrotic herbal medicine: Omics-based mechanistic study

2016- BSc Pharmacology student Mohammed Hussain

Project title: Targeting vitamin A signalling in kidney stem cells to develop novel renal therapy.

2016 A full-time postdoctoral research associate Dr Sudha Priya Soundara Pandi.

Project title: MiR-acles in collecting ducts underlie albuminuria-induced renal fibrosis.

2015 Summer laboratory placements of undergraduate students (Hei Man Fan and Viktoria Sekamov), 1st June-30th August.

2014-2015 A full-time postdoctoral research associate Dr Alessia Fiorentino.

Project title: MiR-acles in collecting ducts underlie albuminuria-induced renal fibrosis.

2014-2015 Visiting Scholar Dr. Fan Qu sponsored by the China Scholarship Council, 12 months

2014-2019 Full-time PhD student Shujun Zhou.

Project title: A proteomic study of an *in-vitro* model of TGF-β1-induced fibrosis and mechanisms of herbal antifibrotics

2014 Postdoctoral visiting fellow Dr. Michael Wang from University of Hong Kong (3 months, April-June)

2013 Full-time MSc. Student Ying Qian, moved on to pharmaceutical industry in China

Project title: An approach to defining retinoic acid- and TGF-beta 1-dependent microRNAs in mIMCD-3 cells

2013 Visiting PhD student Naima Saeed

Project title: *In vitro* anti-fibrotic activities of herbal derivatives

2012 Dr. Fan Qu, Honorary Research Associate (3 months, Jan. – April)

2012 Dr. Jue Zhou, Honorary Research Associate (1.5 months, Jan. – Feb.)

2010-2011 Full-time MSc. Student Qingyang Kong, moved on to a PhD at UCL

Project title: Herbal Regulation of Fibrogenesis in NRK-49F Cells and Expression of Three Retinoic Acid Target Genes in mIMCD-3 Cells

2009-2010 Full-time MSc. Student Shanshan Qu, moved on to pharmaceutical industry in China

Project title: Searching for anti-fibrotic activities from herbal compounds, herbs and herbal mixtures

2009-2012 Dr Halil Uzuner, The Project Manager of the FP7 GP-TCM Consortium. Moved on to be Business Development Manager – Consultancy, at Royal Botanical Gardens, Kew, and since mid-2016, a senior manager at Imperial College London.

Project title: Good Practice of Traditional Chinese Medicine in the Post-genomic Era

2008-2012 Full-time PhD student Yuen Fei Wong. Moved on to postdoctoral fellowship in Chinese University of Hong Kong, an Assistant Professorship at Caritas Institute of Higher Education in Hong Kong and, since mid-2016, a faculty member at the University of Malaya in Malaysia.

Project title: The physiological and pathophysiological roles of retinoids in the postnatal kidneys

2008-2013 Clinical Research Fellow and PhD student Alexandra C Rankin. Moved on to renal medicine consultant position at King's College Hospital.

Project title: Roles for nuclear receptors and lipid-binding proteins in the pro- and anti-fibrotic effects of retinoids

2009 Summer student Xiaxin Liu (King's medical student) for a 1.5-month laboratory exposure (Monday 22nd June until Friday 4th September 2009).

Project title: Laboratory training

2009 Summer student Wing Sun Chung, The Henrietta Barnett School (Monday 24th August 2009 – Friday 18th September 2009).

Project title: Laboratory training

2007-2009 Research Technician and visiting PhD student Qin Hu, who moved on to a postdoctoral fellowship at King's College London.

Project title: Searching for anti-fibrotic activities from herbal compounds, herbs and herbal mixtures

2004-2004 Intercalated BSc. In molecular medicine student Andy D'Silva

Project title: Role of MKP-1 in hypoxia-induced fibronectin expression. (Course Director: Prof. Kaila Srai, Department of Biochemistry)

2003 Postdoctoral fellow Guojie Song (1 month)

Project title: Curcumin induced MKP-1 expression in cell lines

2003 Postdoctoral fellow Weidong Han (5 months)

Project title: Pro-fibrotic factors and retinoid receptor expression

2001-2004 Research technician Ayda Yeganeh

Project title: Intracellular low-density lipoprotein accumulation induced by hypoxia and retinoic acid: potential targets for amelioration of atherosclerosis

1992-1999 Teaching and supervision in China: (i) Supervising medical students and visiting fellows (ii) Supported by Prof. Xiangmei Chen, I organised a national training course on the treatment of chronic renal failure in 1998. The lectures delivered in the training courses were included in a book co-edited by Prof. Xiangmei Chen and me, entitled *Textbook for the Treatment of Chronic Renal Failure*, which was published in 1999

MENTORSHIP

2014- Mentoring in the B-Mentor initiative, a pilot cross-institutional mentoring scheme for Black and Minority Ethnic (BME) academics and researchers in central London. Mentees included Dr Rishma Shah (Lecturer, UCL, 2014-2015), Dr Kofan Chen (PDRA, UCL, 2019-2020) and Dr Nazila Jafari (PDRA, UCL, 2020-present) — Rishma was promoted Senior Lecturer in 2015 and took an Assistant Professorship at University of North Carolina at Chapel Hill; Kofan secured a lectureship at Leicester University in February 2020.
http://www.ucl.ac.uk/hr/equalities/race/BMEntor.php

2014- A mentor in the Gender Ambitions Mentoring Scheme, KCL. Mentees included Dr Christel Koop (Lecturer, 2014-2015) and Dr. (Sofia) Maria Tirados Menendez, a Marie Curie Training Fellow at King's (2016-2017). Christel is now a Senior Lecturer at King's; Sofia went back to Spain to take up an academic position in 2017.

TUTORSHIP & PASTORAL CARE

2024-2025 15 MBBS1-5 Personal Tutees & 3 iBSc Pharmacology tutees.

2020-2024 20 MBBS1-5 Personal Tutees.

2018-2019 15 MBBS1-4 Personal Tutees.

2017- 14 MBBS1-3 Personal Tutees.

2016- 12 MBBS Personal Tutees: 5 Year-1, 4 Year-2 and 5 Year-3.

2015- 8 MBBS Personal Tutees: 5 Year-1 and 3 Year-2.

2014- 3 Year-MBBS1 Personal Tutees.

2000-2003 Honorary Chair (2003), Chair (2002), Vice Chair (2001) and Minister of Academic Affairs (2000), Chinese Students and Scholars Association at UCL.

http://www.cssaucl.org.uk/?page_id=842

2003-2005 Advisor (2004-2006) and Secretary-General (2003), Chinese Students and Scholars Association in the UK.

http://cssauk.org.uk

TEACHING, INCLUDING RECRUITMENT, EXAMINING AND INTERVIEWING

2024- Inclusive Education Bioscience Committee Member

2024-2025 Examining 3h oral presentations on 23rd Apr and written report a week later (6BBM0335)

Examining four MSci Pharmacology Project Design oral presentations (2 hours) and written reports (7BBMM021)

Resurgence of herbal medicinal products. A 1-hour lecture for Bioscience students, 5BBM0213, Semester B, Drugs and Disease, 24th March

Marking 1 oral presentation and written report (6BBM0339), Jan. 2025

Marking 1 oral presentation and written report (7BBM0019), Jan. 2025

2 hours of poster presentation assessments (5BBM0218), 25th Mar. 2025.

2024-2028 Member of Pei-Shan Wang's PhD Thesis Committee (supervisor: Dr Yun Ma)

Chair of PhD Thesis Committee of Sophie Cant (supervisors: Prof Anil Dhawan, Dr. Marianne Samyn, Dr Anita Verma and Dr Eirini Kyrana)

2023-2027 Chair of PhD Thesis Committee of Vivienne Ralph (supervisors: Dr. Sapna Shah and Dr. Kate Bramham; committee members Professor Claire Sharpe and Dr Paramit Chowdhury)

Chair of PhD Thesis Committee of Nicole Whyte (Supervisors: Drs Ragai Mitry and Eirini (Serena) Kyrana; committee members Dr Niloufar Safinia and Yun Ma)

2023-2024 Provided 2 BSc Pharmacology library projects and 2 BSc/MSci dry lab projects

External examiner of PhD student, Leicester University (Student Y. Lin, supervisor N. Brunskill, B. Yang), 4th Jan. 2024

First examiner of a BSc Pharmacol. oral presentation (30 min) and a written report (>5000) 6BBM0339 (J. Lin)

First and second marking two BSc Pharmacol. students' oral presentations (40 min each) and written reports (Y. Malik and M. Mentu), 6BBM0319

First examiner of two MSci Pharmacol. oral presentation (15 min each) and written reports (>5000) 7BBM0019 (N. Nassman and W. Casinto)

2022-2023 Provided 3 BSc Pharmacology library projects on targeting ribosome, Enpp and Impdh, respectively (6BBM0319)

MBBS2 Scholarly Project Module, Botanicals and the Kidney: Friends or Foes? (Accepted 6 students)

2021-2022 Examining four MSc Pharmacology Project Design oral presentations (2 hours), 7BBMM013, 19th & 20th April 2022.

Examining five BSc Pharmacology Project Design oral presentations (2.5 hours), 6BBM0335, 20th April 2022.

2 hours of poster presentation assessments (5BBM0218), 29th Mar. 2022.

2020-2021 Two 1-hour Drug Discovery, Complementary and Alternative Medicine SSC lectures (5MBBS203SSC4) on herbal medicine and kidney care, as well as the importance of herbal medicines, esp. traditional Chinese medicine.

MBBS2 Scholarly Project Module, Botanicals and the Kidney: Friends or Foes? Nine students)

2019-2020 Two online offerholders' events, 7.5 hours.

Pre-app Open Week, 1.5 hours.

MSc Pharmacology Assessment Sub-Board Meetings, 8 hours in the year

Pharmacology Departmental Education Committee Meeting to discuss hybrid delivery and projects etc, 8 hours in the year

Two 1-hour Medical Botanical SSC lectures (5MBBS203SSC4) on herbal medicine and kidney care, as well as the importance of herbal medicines, esp. traditional Chinese medicine.

Supervising MSc Pharmacology Literature Dissertation (7BBMM006) of Farnaz Khadiviboroujeni

Supervising MSc Pharmacology Experimental project Modules (7BBMM010) of Farnaz Khadiviboroujeni

The Department of Pharmacology & Therapeutics adopted my proposal for PIs to meet Pharmacology students to share their stories: I met the students in an event "**Speed meeting with Pharmacology students**" organised by the Department, 5-6.30pm, 3rd December 2019

Resurgence of herbal medicinal products. A 2-hour lecture and forum for Pharmacology students, 5BBM0212/3, Drugs and Disease.

Open the laboratory to three second-year undergraduate students on Research Skills in Pharmacology and interviewed by the students, 5BBM0219 (Dec.)

MSc Pharmacology Library Project, Ryesha Higgs

Pharmacology Education Day (September, 4 hours)

Pharmacology Tutorials (4BBY1040), 4 hours

MBBS2 Scholarly Project Module, Botanicals and the Kidney: Friends or Foes? (Eight students)

2018-2019 Chair of Project Design oral presentations & examinations (2 hours), 6BBM0335.

Resurgence of herbal medicinal products. A 1-hour lecture for Year-2 Pharmacology students and examined 25 examination scripts, 5BBM0216.

Examined a BSc Literature Dissertation 6BBM0319, Suzana Arefin (word count >5000)

Open the laboratory to three second-year undergraduate students on Research Skills in Pharmacology and interviewed by the students, 5BBM0219 (Dec.)

Pharmacology Away Day (September, 4 hours) and Departmental Educational Committee Meeting (5 December, 3 hours)

Tutorials (4BBY1040), 6 hours on the 23 and 25 October (Tutorial 1) and 7 December (Tutorial 2).

MBBS2 Scholarly Project Module, Botanicals and the Kidney: Friends or Foes? (Eight students)

Examined 3 MBBS2 students' Scholarly Project Module 1 proposals, 21st May.

Examined four MSc Pharmacology students' Research Project Design Reports (7BBMM013), April-May 2018

Examined full-time PhD student Reem Bakr Bu Saeed; Supervisor: Prof. Peter McCaffery, The University of Aberdeen. 17th April 2018.

Two days of CYO interviews, 12th April 2018 & 30th April

2017-2018 MSc Research Project Design - 7BBMM013, 4 students

Three MBBS3 Library projects, altogether 11 students split into two rotations:

- LP0994 – *Vitamin A in the health and disease of the kidney*.
- LP0995 – *Renal collecting ducts: "Draining pipes" rise to defences?*
- LP0996 – *Nephrotoxic botanicals*

MBBS2 SSC project: *Traditional Chinese medicine: Why should healthcare professionals care about it?* (5MBBS203SSC18, 5 students)

Open the laboratory to three second-year undergraduate students on Research Skills in Pharmacology and interviewed by the students, 5BBM0219 (5th Dec.)

10 hours of Pharmacology Tutorials, in the October and December 2017 and April 2018, 4BBY1040. 2017

Resurgence of herbal medicinal products. A 1-hour lecture for Year-2 Pharmacology students, KCL, 5BBM0216.

2017-2021 Chair of PhD Thesis Committee, Charlotte Woodhouse, supervisor: Professor Alberto Sanchez Fueyo.

2017 A three-hour assessment of undergraduate presentations on herbal remedies 5BBM0213, as part of the 2nd Year Drugs and Disease module, on 1st December.

DIIID & DTIMB PhD Symposium – examined 2 posters and 1 talk (June 2017)

BMS10-T1 Pharmacology Tutorial 3 renal and GI (10th March)

Examined a BSc Literature Dissertation Lauren Spiers 6BBM0319 (word count 6920)

Examined 1 BSc Pharmacology project design (Siqi Yin), 6BBM0335.

A three-hour assessment of undergraduate presentations on herbal remedies 5BBM0213, as part of the 2nd Year Drugs and Disease module, on 5th December.

2016-2017 Eight hours of Pharmacology Tutorials, in the October 2016, December 2016 and May 2017, 4BBY1040.

Two BSc research projects (45 credits):

- Hussain M. Targeting vitamin A signalling in kidney stem cells to develop novel renal therapy.
- Geneci G. Anti-fibrotic herbal medicine: Omics-based mechanistic study.

Three MBBS Library projects, altogether 12 students split into two rotations:

- LP0994 – *Vitamin A in the health and disease of the kidney,* four students, including two in rotation 1 (Grace J, Johnson G) and two in rotation 2.
- LP0995 – *Renal collecting ducts: "Draining pipes" rise to defences? Four students,* including one in rotation 1 (Burke C, Movsesyan M) and two in rotation 2.
- LP0996 – *Nephrotoxic botanicals, four students,* including two in rotation 1 (Johnston A, Salahudin Z) and two in rotation 2.

2016-2020 Admissions Tutor, Department of Pharmacology and Therapeutics.

2016- MRes/MSc in Pharmacology organiser of Literature Dissertation (7BBMM006), Research Projects (7BBMM010 and 7BBMM015) and Contemporary Developments modules (7BBMM012).

2016-2020 PhD Thesis Committee Chair of Chiou-Tsun Tsai, Supervisor: Prof. Eric So, KCL.

2016 Open the laboratory to three second-year undergraduate students on Research Skills in Pharmacology and interviewed by the students, 5BBM0219 (6th Dec.)

Examined three posters and one oral presentation, DTIMB/DIIID PhD Showcase Day, 11th July.

A three-hour assessment of undergraduate presentations on herbal remedies 5BBM0213, as part of the 2nd Year Drugs and Disease module, December.

Resurgence of herbal medicinal products. A 1-hour lecture for Year-2 Pharmacology students, KCL.

Examined 48 students.

PhD examiner of Z Zwaini, Leicester University; supervisors: Dr C Stover and Dr B Yang; project title: Renal ischemia and reperfusion – establishment of an *in vitro* model, of a murine *in vivo* model, and retrospective analysis of clinical specimen.

PhD examiner of Y Neo, Cambridge University; supervisor: Dr TP Fan; project title: Protective Effects of QiDengMingHu Herbal Formulation in *In-Vitro* and *In-Vivo* Models of Vascular Disruption.

Second examiner of M. Rahman's MSc research project Effects of the nanoparticles on microencapsulated islet transplantation outcomes (10,000 words). Supervisor, Dr Aileen King, programme ID: 6BBM0309 (19th Jan.)

Interviewing MBBS students, three half-days (8th, 11thJan. and 5th Feb.)

2015- MSc Pharmacology Assessment Board

2015- Contributed a KBI MRes-PhD project entitled *miR-acles in collecting ducts underlie kidney scarring driven by risk factors.* Xu Q (1st supervisor), MacDougall I (2nd supervisor).

2015- MSc Pharmacology library poster tutorial, July, 5 students, 2 hours.

2015- MSc Pharmacology project poster tutorial, August, 5 students, 1 hour.

2015-2018 PhD Thesis Committee Member of Mazdak Ehteramyan, Supervisor: Dr Lingfang Zeng, KCL

2015-2016 12 Pharmacology tutorials for MBBS students, covering four major subjects: General aspects of drugs and receptors, cholinergic and adrenergic neurotransmission, coronary disease, and arrhythmias.

MBBS Library projects, altogether 16 students split into two rotations:

- LP0994 – *Vitamin A in the health and disease of the kidney,* seven students, including three in rotation 1 (Sunderland A, Thedchanamoorthy A and Hakim U) and four in rotation 2 (Mangal A, Javaid A, Golsharifi M and Zoella J).
- LP0995 – *Renal collecting ducts: "Draining pipes" rise to defences? Four students,* including one in rotation 1 (Ali N) and three in rotation 2 (Nadheem M, Griffith K and Francis R)

- LP0996 – *Nephrotoxic botanicals, four students,* including two in rotation 1 (Holden F, Bawa T) and three in rotation 2 (Yogamayagam N, Raveendranathan T)

Eight hours of Pharmacology Tutorials, on the 27th-28th October 2015, 4th Dec. 2015 and 4th May 2016, 4BBY1040.

2015 A three-hour assessment of undergraduate presentations on herbal remedies 5BBM0213, as part of the 2nd Year Drugs and Disease module, on 1st Dec.

Open the laboratory to three second-year undergraduate students on Research Skills in Pharmacology and interviewed by the students, 5BBM0219 (1st Dec.)

Interview panel members of two postdoctoral fellows at King's.

Examined full-time KBI PhD student D. Johnson: PhD project proposal report and presentation examinations; Supervisor: Prof. G Lombardi and Prof. R Botnar, KCL (8 hours).

MSc Pharmacology Contemporary Developments posters, 5 students, 21st August and 1st September.

Chairing the PhD Upgrade Viva of Merritt E, King's.

Examined full-time MSc student Sara Rizvi research project dissertation: *Effect of HDAC7 Derived 7aa Peptide on the Differentiation of Vascular Progenitor Cells*; Supervisor: Dr Lingfang Zeng, KCL.

MSc Pharmacology project poster examination, 5 students, July.

Examined full-time MSc student Sara Rizvi library dissertation: *Epithelial-to-Mesenchymal Transition*; Supervisor: Dr Lingfang Zeng, KCL.

Examined full-time KBI MRes/PhD student D. Johnson: module I rotation project presentation and report examination; Supervisor: Prof. G Lord and Dr M. Hernandez-Fuentes, KCL (6 hours).

Examined full-time PhD student Irbaz Badshah; Supervisor: Dr Mark Dockrell, St George's, University of London.

Lead the development of extramural year work experience of BSc students in universities and companies specialised in traditional Chinese medicine.

Two 2-hour Pharmacology tutorial focused on the kidney.

Resurgence of herbal medicinal products. A 1-hour lecture for Year-2 Pharmacology students, KCL, Feb. 2015

2014-2015 Provision of literature and laboratory projects for MSc Pharmacology students.

2014- Chairing the 1st PhD Thesis Committee Meeting of Merritt E, King's.

Dec. 2014 Pharmacology project marking.

Dec. 2014 A three-hour assessment of undergraduate presentations on herbal remedy as part of the 2nd Year Drugs and Disease module, on 1st December.

Dec. 2014 Two 2-hour Pharmacology Tutorials on 5th and 10th December.

Oct. 2014 Two 2-hour Pharmacology Tutorials on 28th and 29th October.

2013 Examined full-time MSc. Student Vadivel Anitha Banu, Project title: Multifunctional Nano-encapsulation of pancreatic islets for improving the outcome of transplantation. Supervisor: Zheng-Liang Zhi, KCL.

2013 Examined full-time MSc. Student Ying Qian, Project title: An approach to defining retinoic acid- and TGF-beta 1-dependent microRNAs in mIMCD-3 cells. Supervisors: Qihe Xu, Bruce Hendry, KCL.

2013 Examined full-time PhD student transfer report, Dario Ummarino; Supervisor: Dr. Lingfang Zeng, KCL.

2013 Examined full-time PhD student Sonia Nanescu; Supervisor: Prof. Peter Mccaffery, The University of Aberdeen.

2011 Full-time MSc. Student Qingyang Kong; Supervisor: Dr. Qihe Xu, KCL.

2011 Examined full-time MSc. Student Mahima Kalra; Supervisor: Dr. Yu Wai Chen, KCL.

2010 Objective structured clinical examination (OSCE) for medical students (12^{th}-13^{th} August), PHASE 3, KCL.

2010 Full-time MSc. Student Shanshan Qu; Supervisor, Dr. Qihe Xu, KCL.

2010 Full-time MSc. Student Malgorzata Furmanik; Supervisor, Prof. Catherine Shanahan, KCL.

2005 Vishal Luther, Intercalated BSc. In Molecular Medicine research project, Department of Biochemistry, UCL.

2005 Bhavni Patel, Intercalated BSc. In Molecular Medicine research project, Department of Biochemistry, UCL.

2004 Andy D'Silva, Intercalated BSc. In Molecular Medicine research project, Department of Biochemistry, UCL.

2004 Tracey Parker, Intercalated BSc. In Molecular Medicine research project, Department of Biochemistry, UCL.

EXECUTIVE SUMMARY HIGHLIGHTING RESEARCH DISCOVERIES

1. Mobilising retinoic acid signalling for the defence against kidney diseases: Vitamin A and its activated derivatives, retinoic acids (RA), are indispensable for kidney development. My research has focused on their roles in adult kidneys. Despite some promising therapeutic properties, we found that RA has dual effects on renal fibrosis. Supported by Kidney Research UK (KRUK), my PhD student Dr A. Rankin found that induction of PAI-1 and suppression of matrix degradation accounted for the pro-fibrotic effect of RA in renal fibroblasts, mainly through activating the RXR pathway. Also supported by KRUK, my PhD student Dr Y. F. Wong found that mouse kidneys were characterised by activities of RA and its receptors (RARs) in collecting ducts (CDs). Using a transcriptomic approach, she and my KRUK postdoctoral fellow Dr A. Papadimitriou catalogued RA/RAR-dependent mRNAs and microRNAs in CD cells, suggesting that RA/RAR antagonise infection and inflammation by regulating mRNA expression, but regulate fibrosis mainly through regulating microRNAs. We hypothesise that the RA/RAR signalling in CDs is a critical protection against tubulointerstitial injury in acute kidney injury (AKI) and chronic kidney disease (CKD). In support of this, we found that RA/RAR activity in CD cells is a convergence point of regulation by mediators of AKI and CKD. Revolving around this hypothesis, my current studies funded by KRUK aim to understand roles for the endogenous RA/RAR system and its target genes in health and disease of the kidney and to develop novel preventive and therapeutic strategies. Along this line of interest, I am also keen to understand whether tonifying herbal entities used in traditional Chinese medicine (TCM) may play an important role in AKI/CKD clinical management by mobilising kidney defending mechanisms, including the RA/RAR signalling in CDs.

2. Integrative Chinese medicine and antifibrotic and profibrotic botanicals: TCM is mainstream in China. Supported by KRUK, we conducted TCM knowledge-based rediscovery of anti-fibrotic and pro-fibrotic activities. Sixteen herbal formulations, 11 herbs and 5 herbal compounds were validated to be antifibrotic and two herbs were identified to have reproducible pro-fibrotic activities. These led to (i) award of the €1.0m FP7 *Good Practice in Traditional Chinese Medicine in the Post-genomic Era* grant (GP-TCM), and two UK-China collaborative grants on TCM research; (ii) founding of the *Good Practice in Traditional Chinese Medicine Research Association* (GP-TCM RA), which is a UK-based charity, an EMA/HMPC Interested Party and an international society dedicated to promoting good practices in TCM research using modern technologies; and (iii) founding of the *King's Centre for Integrative Chinese Medicine* (CICM), a new research and teaching initiative of King's Health Partners. The centre focuses on good practices and international cooperation, and particularly emphasises research of anti- and pro-fibrotic botanicals using an omics-based approach, which was pioneered by Dr S. Zhou, the first CICM PhD student, who graduated in 2019. Other interests include roles for nephrotoxic and tonifying TCM drugs in AKI & CKD.

3. Top ten discoveries from primary research

Discoveries #1-7 on retinoic acid signalling:

- **Discovery #1:** Different roles of RAR isotypes and RXR in RA-mediated defence against cellular oxidative stress and apoptosis by inducing MKP-1, which switches off MAP kinase-AP-1 signalling (*JBC* 2001, 2002, *Free Radic Biol Med.* 2004), supporting selectively targeting RAR isotypes and inducing defence molecules, e.g., MKP-1, for optimised nephroprotective therapies.
- **Discovery #2:** Despite promising therapeutic efficacy of RA in puromycin-induced nephrosis in rats (*Br J Pharmacol* 2003) and in many other kidney disease animal models (*Kidney Int* 2004), it dose-dependently increased MIF expression and promote lipid uptake (*Kidney Int* 2004), synergizes with TGF-β1 in inducing fibrogenesis by reducing MMP activity, increasing PAI-1 expression and repressing collagen degradation, mainly by activating RXR (*Br J Pharmacol* 2013), and it dose-dependently increases mortality and renal fibrosis in Alb/TGF-β1 transgenic mice (*Nephron Exp Nephrol* 2010), highlighting hormesis and a Janus face of RA.
- **Discovery #3:** RA/RAR signalling is indispensable for embryonic kidney development, but its role in the health and disease of the kidney is obscure. In mouse kidneys, we found that RA remains abundant in healthy young and adult kidneys but is depleted from the kidneys of Alb/TGF-β1 mice, preceding the development of kidney fibrosis (*Nephron Exp Nephrol* 2010). This discovery supports

RA/RAR continues to play an active role in young and adult kidneys and its dysregulation may play a role in TGF-β1-induced fibrosis and thus could be a potential therapeutic target.

- **Discovery #4:** RA/RAR activity is physiologically confined to the renal CD tubules (*PLoS One* 2011) and we have further catalogued the genes dependent on the endogenous RA/RAR activity in mouse inner medullary CD cells. Many of these RA/RAR-dependent genes have important defence roles against infection, inflammation, fibrosis and cystogenesis (*PLoS One* 2012).
- **Discovery #5:** Using *RARE-Luc* mice as a reporter model for visualising endogenous RA/RAR activity, we found that different nephrotoxic agents (aristolochic acid, gentamicin and cisplatin) induce similar AKI, in terms of increased SCr and BUN levels, but they differentially regulate renal RA/RAR activity (UK Kidney Week 2019). Further understanding these intriguing differences may guide precision prevention and treatment of AKI induced by different nephrotoxic agents.
- **Discovery #6:** RA/RAR activity in CD cells is identified as a convergence point of regulation by the multiple factors involved in AKI and CKD. Compared with aged-matched normal human CD cells, CD-derived autosomal recessive polycystic kidney disease (ARPKD) renal cyst cells have much repressed RA/RAR activity. RA/RAR activity responds in an opposite fashion to mediators of kidney injury (induced by gentamicin and aristolochic acid I; repressed by cisplatin and endotoxin), mediators of hypertension (induced by endothelin-1, vasopressin and norepinephrine; repressed by aldosterone and angiotensin II) and neurotransmitters (induced by CGRP and norepinephrine; repressed by acetylcholine). Further investigations into the mechanisms and biological consequences of RA/RAR activity changes induced by these factors may facilitate a deeper understanding of the heterogeneity and multifactorial nature of AKI and CKD and guide refined and stratified treatment (*Sci Rep* 2020). Intriguingly, we found that RARα agonist RA-568, to which King's has intellectual property rights, but not RA per se, rescues the RA/RAR activity in CD cells repressed by albumin, high glucose, angiotensin II, aldosterone, cisplatin and endotoxin, supporting a potential therapeutic value of this promising compound (*Sci Rep* 2020).
- **Discovery #7:**: snRNA-seq and scRNA-seq studies have identified glomerular parietal epithelial cells (PECs) as the major site of expression of *ALDH1A2* and *Aldh1a2* genes in humans and mice, respectively. Analysis of the genes of the vitamin A metabolome and RA signalling has led us to hypothesize that RA biosynthesis catalyzed by Aldh1a2/ALDH1A2 in PECs may play an important role in kidney health and disease in an autocrine and/or paracrine fashion (*Exp Biol Med* 2024). Our ongoing genomic and deep phenotyping analyses have revealed significant links between specific *ALDH1A2* genetic variants with glomerular basement membrane duplication, glomerular tip lesions, crescent formation, interstitial oedema, cardiac artery disease, chronic kidney disease progression, as well as dysregulated lipid metabolism.

<u>Discoveries #8-10 on fibrosis and antifibrotics:</u>

- **Discovery #8:** We found that, by controlling coating surfaces of multi-cell plates, TGF-β-induced fibrogenesis in fibroblasts in either a monolayer or nodules can be developed into innovative 2D and 3D cellular models of fibrosis suitable for high-throughput visualisation and quantification of fibrogenesis (*Am J Physiol Renal Physiol* 2007). This innovative methodology has been cited 126 times and greatly accelerated discoveries of novel antifibrotic and profibrotic activities, as well as related mechanistic studies, both within my own lab and beyond.
- **Discovery #9:** Using the above model, we have discovered a series of antifibrotic and profibrotic herbal activities (*NDT* 2009 with 117 citations and highlighted by *Science* in 2014. Some herbal remedies approved for treating liver fibrotic diseases in China and showing outstanding antifibrotic activities in our studies have progressed to FDA-approved clinical trials for the treatment of refractory liver fibrosis (e.g., Fuzheng Huayu granules, ClinicalTrials.gov Identifier: NCT00854087).
- **Discovery #10:** Our proteomic analyses found that TGF-β-induced *in vitro* model of fibrosis in renal fibroblasts is an intracellular metabolic disorder, characterised by dysregulation of a series of intracellular metabolic pathways and enzymes, and extracellular proteins (*Sci Rep* 2020) and that Scutellariae Radix, baicalein and a synthetic Alk5 inhibitor IN1130 have overlapping effects in regulating dysregulated pathways and proteins (*Phytomedicine* 2022).

EXECUTIVE SUMMARY HIGHLIGHTING TEACHING INNOVATION

1. Undergraduate Medical Education (MBBS):

- Block lead, 4MBBS102 Fundamentals of Physiology and Pharmacology for MBBS stage-1 students since 2023-2024, 140 hours of personal contact.
- Having served as Personal Tutor of Year 1, 2, 3, 4 and 5 medical (MBBS1-5) students since 2015, with up to 20 students per year. Developed and applied the innovative and popular "APP" (Adulthood, professionalism and proactiveness) principles to guide my tutees.
- Having supervised an MBBS Scholarly Project Module on herbal medicine (5MBBS30) since 2018, nine to twelve students per year, leading to publications in PhytoMedicine, etc. One student commented: "I really enjoyed the module under your supervision, and I hope to do some more work on herbal medicine in the future - it is not only a fascinating subject but now I understand its importance!"
- Having developed two Student Selected Components (SSC) lectures on herbal medicine since 2020 (5MBBS203SSC4, Drug Discovery, Complementary and Alternative Medicine).
- Supervised four MBBS3 SSC modules (2014-2018), one of which led to a publication co-authored with students, entitled "Taming the fire of nephrotoxic botanicals", two press releases by KCL and Kidney Research UK, as well as by the official journal of British Renal Society *Journal of Kidney Care*.

2. Undergraduate Biosciences Education (BSc and iBSc Pharmacology):

- Member of the Inclusive Education Bioscience Committee since 2024
- Served as Admissions Tutor Pharmacology in 2015-2020; organised Open Days, Offer-Holder Days, interviews, transfers and other admissions related activities.
- Having lectured Bioscience students on the increasing importance of herbal medicine since 2020 (5BBM0212/3, Drugs and Disease). After one of the latest lectures, one student e-mailed me, commenting: "My name is xxx, I attended your Drugs and disease B: Resurgence of HMPs lecture yesterday 14/03. I am glad that Andy put your and Anne Pollock's lectures on our syllabus. I appreciate the initiative you and King's have taken to bring back this knowledge to us. I think it is very important, ... I especially appreciated that you reinforced the idea that it is not just herbal medicines, but the wisdom of the practitioners on how to use them that makes a combined therapeutic benefit in traditional Chinese medicine and other HMs. I think if given the funding and research a lot of herbal medicines hidden in different parts of the world could prove beneficial. A critical eye is key as you said, but I believe that even though we know more now, the knowledge our ancestors compiled is a resource we shouldn't disregard."
- Supervisor of BSc and iBSc Pharmacology students' Experimental Projects and library projects. My student M. Gallacher was awarded British Pharmacology iBSc Research Project Prize, the only one in the Department for the year (2019).
- Since 2024, iBSc Pharmacology organiser. Oversaw the development of promotion videos of the iBSc Programme and the iBSc Pharmacology course, and the revision to the iBSc Pharmacology web page.
- Since 2024, lead of the Fundamentals of physiology & pharmacology (FPP) block, the physiology and anatomy of systems module (PAS), MBBS stage-1.
- Since 2024, lecturer Pharmacy students the pharmacology workshop "Organ Bath and Simulation" 4BBP0131.

3. Pharmacology Master Programme:

- Since 2015, having organised 4 MSc/MRes Pharmacology modules, accounting for 58% all the credits of the programme. Starting from 6 students in 2014-2015, this popular programme grew steadily in the following eight years. The 2021-2022 cohort of 25 students are the largest

ever of this programme. In 2016-2018, the MSc/MRes Pharmacology programme was one of only 2 programmes across the whole University to achieve 100% satisfaction rate in 3 consecutive years in national surveys.

- Commenting on the Contemporary Developments poster design module of the 2015-2016 cohort, Prof Peter McNaughton, Director of the MSc/MRes Pharmacology programme at the time, commented: “The best group of Contemporary Developments posters in the past few years”.
- In 2018, Co-Director Dr Andy Grant commented, “Quality of the posters have significantly increased since Qihe took over as organiser.”
- In 2018, both the MSc/MRes Experimental Projects (7BBMM010; 7BBMM015) and Literature Dissertation (7BBMM006) modules have been ranked highly by our students: (4.5 out of 5) and the students have ranked their improvements in poster design skills very highly too (4.5 out of 5). One project supervisor Dr Mike Curtis commented: “Excellent course management!” Another supervisor Dr Aleksandar Ivetic added: “Many congratulations on running this course. I think you’ve really organised it well for the supervisors. The information you’ve laid out at every step is extremely comprehensive and important.”
- In 2018, I supervised 4 students’ Project Design Modules of the MSc/MRes Pharmacology programme. One of the students offered feedback by e-mail: “thank you for your guidance and advice throughout our project design module. Your advice was very helpful in preparing the final proposal as well as revealing some weakness in study design that we did not see at first. It was an overall enjoyable and informative exercise which I'm sure will be useful in the future as all scientists need to write grants.” Dr Lawrence Moon, the module organiser added: “I want to add my thanks to xxx (name of the student)! The module ran very smoothly this year and I appreciate you being one of the supervisors. I enjoyed listening to the oral presentations from your group; it was a very interesting idea that they pursued.” Professor Peter McNaughton Director of the MSc/MRes Pharmacology programme who examined my students commented: “Both Lawrence and I thought this was a tremendously exciting project, and all the reports were in my opinion first class.”
- In 2024, after MSc Pharmacology Experimental Project Poster assessments, Professor Luigi Gnudi, one of the supervisors and examiners e-mailed: "Thanks, Qihe. Always a pleasure working together". Professor Prof Peter McNaughton, an examiner, added: "Agree with Luigi – your cheerful approach made it a great pleasure to work together, both for us and (I’m sure) also for the students". Dr Qiuping Zhang, another examiner, added:" Totally agree with Luigi and Peter, thank you very much h for all of your hard work. You are a star!"

  Professor Stuart Bevan, Director of the MSc Pharmacology Programme, commented: "Thank you for all your efforts to support the MSc Pharmacology course over the years. Your efforts have been invaluable to ensure the smooth running of the programme. The project placement module is a key element in the course and one that students find very rewarding. It is often an important experience for them in deciding their future path. You could see from the smiles yesterday that they had enjoyed the module."

4. Postdoc and PhD Supervision

- Supervision of 4 postdoctoral scientists and 3 PhD students;
- Chair of 6 PhD Thesis Committees.

5. Other Teaching and Mentorship Roles and Leadership

- Member of the Inclusive Education Committee, School of Biosciences, King's College London (2024-present).
- Elected to the University Academic Board (2012-2016) and having sat on BSc Pharmacology Education Committee and MSc Pharmacology Assessment Sub-Board since 2014;
- Mentored 4 junior academics in B-Mentor and Gender Ambitions schemes; and
- Having led the development of CICM teaching programmes and related international cooperation since 2013.